

2018

ALTHOFF P, SCHMIEGEL W, LANG G, NICOLAS V, BRECHMANN T.
Creeping Fat Assessed by Small Bowel MRI Is Linked to Bowel Damage and Abdominal Surgery in Crohn's Disease.

Dig Dis Sci. 2018 Oct 1. doi: 10.1007/s10620-018-5303-1. [Epub ahead of print]

Impact Factor: 2,550

Affiliation BGH

BARANISKIN A, CHOMIAK M, AHLE G, GRESS T, BUCHHOLZ M, TUREWICZ M, EISENACHER M, MARGOLD M, SCHLEGEL U, SCHMIEGEL W, HAHN S, SCHROERS R.

MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.

J Neurooncol. 2018 Jan 11. doi: 10.1007/s11060-018-2749-0. [Epub ahead of print]

Impact Factor: 3,060

ENGEL C, VASEN HF, SEPPÄLÄ T, ARETZ S, BIGIRWAMUNGU-BARGEMAN M, DE BOER SY, BUCKSCH K, BÜTTNER R, FEDER EH, HOLZAPFEL S, HÜNEBURG R, JACOBS MAJM, JÄRVINEN H, KLOOR M, VON KNEBEL DOEBERITZ M, KOORNSTRA JJ, VAN KOUWEN M, LANGERS AM, VAN DE MEEBERG PC, MORAK M, MÖSLEIN G, NAGENGAST FM, PYLVANAINEN K, RAHNER N, RENKONEN-SINISALO L, SANDULEANU S, SCHACKERT HK, SCHMIEGEL W, SCHULMANN K, STEINKE-LANGE V, STRASSBURG CP, VECHT J, VERHULST ML, DE VOS TOT NEDERVEEN CAPPEL W, ZACHARIAE S, MECKLIN JP, LOEFFLER M; German HNPCC Consortium, the Dutch Lynch Syndrome Collaborative Group, and the Finnish Lynch Syndrome Registry.

No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies.

Gastroenterology. 2018 Jul 29. pii: S0016-5085(18)34818-2. doi:

10.1053/j.gastro.2018.07.030. [Epub ahead of print]

Impact Factor: 16,716

KLEIN-SCORY S, MASLOVA M, POHL M, EILERT-MICUS C, SCHROERS R, SCHMIEGEL W, BARANISKIN A.

Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer.

Transl Oncol. 2018 Jan 19;11(2):213-220. doi: 10.1016/j.tranon.2017.12.010. [Epub ahead of print]

Impact Factor: 3,071

RÖSCH T, ALTENHOFEN L, KRETSCHMANN J, HAGEN B, BRENNER H, POX C, SCHMIEGEL W, THEILMEIER A, ASCHENBECK J, TANNAPFEL A, VON STILLFRIED D, ZIMMERMANN-FRAEDRICH K, WEGSCHEIDER K.

Risk of Malignancy in Adenomas Detected During Screening Colonoscopy.

Clin Gastroenterol Hepatol. 2018 Jun 11. pii: S1542-3565(18)30596-2. doi:

10.1016/j.cgh.2018.05.043. [Epub ahead of print]

Impact Factor: 7,896

VOGL TJ, PEREIRA PL, HELMBERGER T, SCHREYER AG, SCHMIEGEL W, FISCHER S, HERZOG C. [Updated S3 Guidelines - Diagnosis and Treatment of Colorectal Carcinoma: Relevance for Radiological Diagnosis and Intervention].

Rofo. 2018 Sep 26. doi: 10.1055/a-0750-1762. [Epub ahead of print] German. No abstract available.

Kein Impact Factor

VOGL TJ, PEREIRA PL, SCHREYER AG, SCHMIEGEL W, FISCHER S, HERZOG C.

Updated S3 Guidelines - Diagnosis and Treatment of Colorectal Carcinoma: Relevance for Radiological Diagnosis and Intervention.

Rofo. 2018 Sep 24. doi: 10.1055/a-0721-1947. [Epub ahead of print] English, German.

Kein Impact Factor

Zuzüglich noch die 3 Artikel gemäß Prof. Schmiegel, zu denen ich die komplette Autorenliste (noch) nicht vorliegen habe:

Al-Batran SE, ...Schmiegel W,... D. Hofheinz RD. Peri-operative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin, and epirubicin for locally advanced, resectable gastric or gastro-esophageal junction adenocarcinoma (FLOT4): a phase 2/3, open-label, randomized controlled trial. Lancet, 2018. In press.

Vangala DB, ... Schmiegel W. Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. European Journal of Cancer, 2018. In press.

Baraniskin A, ... Schmiegel W., Heinemann V. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. European Journal of Cancer, 2018. In press.

2017

AHLE G, TOUITOU V, CASSOUX N, BOUYON M, HUMBRECHT C, OESTERLÉ H, BARANISKIN A, SOUSSAIN C, NGUYEN-THEM L, GAULTIER C, HOANG-XUAN K, HOUILLIER C.

Optic Nerve Infiltration in Primary Central Nervous System Lymphoma.

JAMA Neurol. 2017 Nov 1;74(11):1368-1373. doi: 10.1001/jamaneurol.2017.2545.

Kein Impact Factor

AL-BATRAN S, HOMANN N, SCHMALENBERG H, KOPP HG, HAAG GM, LULEY KB, SCHMIEGEL WH, FOLPRECHT G, PROBST S, PRASNIKAR N, THUSS-PATIENCE PC, FISCHBACH W, TROJAN J, KOENIGSMANN M, PAULIGK C, GOETZE TO, JAEGER E, MEILER J, SCHULER MH, HOFHEINZ R. Perioperative chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a randomized, multicenter phase 3 trial

Journal of Clinical Oncology 2017 35:15_suppl, 4004-4004

Impact Factor: 1,667

BARANISKIN A, VAN LAETHEM JL, WYRWICZ L, GULLER U, WASAN HS, MATYSIAK-BUDNIK T, GRUENBERGER T, DUCREUX M, CARNEIRO F, VAN CUTSEM E, SEUFFERLEIN T, SCHMIEGEL W. Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona.

Eur J Cancer. 2017 Nov;86:305-317. doi: 10.1016/j.ejca.2017.09.021. Epub 2017 Oct 21. Review.

Impact Factor: 6,029

BINDER H, HOPP L, SCHWEIGER MR, HOFFMANN S, JÜHLING F, KERICK M, TIMMERMANN B, SIEBERT S, GRIMM C, NERSISYAN L, ARAKELYAN A, HERBERG M, BUSKE P, LOEFFLER-WIRTH H, ROSOLOWSKI M, ENGEL C, PRZYBILLA J, PEIFER M, FRIEDRICHS N, MOESLEIN G, ODENTHAL M, HUSSONG M, PETERS S, HOLZAPFEL S, NATTERMANN J, HUENEBURG R, SCHMIEGEL W, ROYER-POKORA B, ARETZ S, KLOTH M, KLOOR M, BUETTNER R, GALLE J, LOEFFLER M.

Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome. J Pathol. 2017 Oct;243(2):242-254. doi: 10.1002/path.4948. Epub 2017 Sep 5.

Impact Factor: 6,894

BIRNDT S, SCHENK T, HEINEVETTER B, BRUNKHORST FM, MASCHMEYER G, ROTHMANN F, WEBER T, MÜLLER M, PANSE J, SCHROERS R, BRAESS J, FRICKHOFEN N, JANKA G, LEHMBERG K, LACHMANN G, HOCHHAUS A, ERNST T, LA ROSÉE P.

Hemophagocytic lymphohistiocytosis (HLH): a cytokine storm disorder mimicking sepsis and a diagnostic pitfall on intensive care units

Oncol Res Treat 2017;40(suppl 3):1-308 Meeting Abstract: V685 Published: SEP 2017

<https://doi.org/10.1159/000479566>

Impact Factor: 1,667

BRECHMANN T, MAIER C, KAISLER M, VOLLERT J, SCHMIEGEL W, PAK S, SCHERBAUM N, RIST F, RIPHAUS A.

Propofol sedation during gastrointestinal endoscopy arouses euphoria in a large subset of patients.

United European Gastroenterol J. 2018 May;6(4):536-546. doi: 10.1177/2050640617736231. Epub 2017 Oct 4.

Impact Factor: 3,477

Affiliation BGH

BRECHMANN T, SPERLBAUM A, SCHMIEGEL W.

Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: Results of a retrospective cohort study.

World J Gastroenterol. 2017 Feb 7;23(5):842-852. doi: 10.3748/wjg.v23.i5.842.

Impact Factor: 3,365

Affiliation BGH

DIETZ J, SUSSER S, VERMEHREN J, PEIFFER KH, GRAMMATIKOS G, BERGER A, FERENCI P, BUTI M, MÜLLHAUPT B, HUNYADY B, HINRICHSEN H, MAUSS S, PETERSEN J, BUGGISCH P, FELTEN G, HÜPPE D, KNECHT G, LUTZ T, SCHOTT E, BERG C, SPENGLER U, VON HAHN T, BERG T, ZEUZEM S, SARRAZIN C; European HCV Resistance Study Group.

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.

Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13

Impact Factor: 16,716

KAKKASSERY V, SCHROERS R, COUPLAND SE, WUNDERLICH MI, SCHARGUS M, HEINZ C, WASMUTH S, HEILIGENHAUS A, AHLE G, LENOBLE P, SCHLEGEL U, SCHMIEGEL W, DICK HB, BARANISKIN A.

Vitreous microRNA levels as diagnostic biomarkers for vitreoretinal lymphoma.

Blood. 2017 Jun 8;129(23):3130-3133. doi: 10.1182/blood-2017-01-765180. Epub 2017 Apr 7. No abstract available.

Impact Factor: 13,164

KASENDA B, IHORST G, SCHROERS R, KORFEL A, SCHMIDT-WOLF I, EGERER G, VON BAUMGARTEN L, RÖTH A, BLOEHDORN J, MÖHLE R, BINDER M, KELLER U, LAMPRECHT M, PFREUNDSCHUH M, VALK E, FRICKER H, SCHORB E, FRITSCH K, FINKE J, ILLERHAUS G.

High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.

Leukemia. 2017 Dec;31(12):2623-2629. doi: 10.1038/leu.2017.170. Epub 2017 May 31.

Impact Factor: 11,702

KOLLMANN CM, SCHMIEGEL W, BRECHMANN T.

Gastrointestinal endoscopy under sedation is associated with pneumonia in older inpatients-results of a retrospective case-control study.

United European Gastroenterol J. 2018 Apr;6(3):382-390. doi: 10.1177/2050640617735059. Epub 2017 Sep 27.

Affiliation BGH

Impact Factor: 3,477

KORFEL A, SCHROERS R, SCHLEGEL U, SCHMITZ N, HOFER S, BAIREY O, SCHMIDT-HIEBER M, HIRSCH A, REIMER P, MARTUS P.

Secondary CNS involvement in malignant lymphoma: data from a multicenter prospective international registry

Neuro Oncol. 2017 May; 19(Suppl 3): iii104.

Published online 2017 Apr 19. doi: [10.1093/neuonc/nox036.397]

Impact Factor: 7,786

PETERSEN D, NAVEED P, RAGHEB A, NIEDIEKER D, EL-MASHTOLY SF, BRECHMANN T, KÖTTING C, SCHMIEGEL WH, FREIER E, POX C, GERWERT K.

Raman fiber-optical method for colon cancer detection: Cross-validation and outlier identification approach.

Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jun 15;181:270-275. doi: 10.1016/j.saa.2017.03.054. Epub 2017 Mar 25.

Impact Factor: 2,536

PLATZBECKER U, LENGFELDER E, SCHAFFER-ECKART K, GOTZE KS, HEUSER M, THOL F, SALIH HR, HANEL M, SPIEKERMANN K, MARTIN S, MACHHERNDL-SPANDL S, KUNZMANN V, JAKOB A, TISCHLER HJ, NIEMANN D, MEZGER J, BOCHTLER T, KRAUSE S, DE WIT M, BALDUS CD, GREIL R, GREINER J, RINGHOFFER M, RADSAK M, WATTAD MA, SCHMIEGEL W, KOLLER E, HEITS F, REICHEL A, KREMERS S, HOCHHAUS A, BASARA N, WOLF D, GOERNER M, SCHAICH M, BIRSACK H, KIRCHEN H, KUBIN T, ASCHAUER G, HESSE T, LINK H, DUERK H, KUERSCHNER D, FIEDLER W, HERTENSTEIN B, PUTTRICH M, KRAMER M, SAUER M, HIDDEMANN W, DUEHRSEN U, SERVE H, THIEDE C, GANSER A, BRUMMENDORF TH, DOHNER K, BORNHAUSER M, SCHLENK RF, ROLLIG C, DOHNER H, EHNINGER G, PASCHKA P.

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry
BLOOD Volume: 130 Supplement: 1 Meeting Abstract: 2618 Published:DEC 7 2017
Impact Factor: 13,164

RIPHAUS A, WEHRMANN T, KRONSHAGE T, GEIST C, POX CP, HERINGLAKE S, SCHMIEGEL W, BEITZ A, MEINING A, MÜLLER M, VON DELIUS S.
Clinical value of the Integrated Pulmonary Index® during sedation for interventional upper GI-endoscopy: A randomized, prospective tri-center study.
Dig Liver Dis. 2017 Jan;49(1):45-49. doi: 10.1016/j.dld.2016.08.124. Epub 2016 Sep 1.
Impact Factor: 3,061

SCHMIEGEL W, BUCHBERGER B, FOLLMANN M, GRAEVEN U, HEINEMANN V, LANGER T, NOTHACKER M, PORSCHEN R, RÖDEL C, RÖSCH T, SCHMITT W, WESSELMANN S, POX C.
S3-Leitlinie – Kolorektales Karzinom.
Z Gastroenterol. 2017 Dec;55(12):1344-1498. doi: 10.1055/s-0043-121106. Epub 2017 Dec 6. German. No abstract available.
Impact Factor: 1,618

SCHMIEGEL W, SCOTT RJ, DOOLEY S, LEWIS W, MELDRUM CJ, POCKNEY P, DRAGANIC B, SMITH S, HEWITT C, PHILIMORE H, LUCAS A, SHI E, NAMDARIAN K, CHAN T, ACOSTA D, PING-CHANG S, TANNAPFEL A, REINACHER-SCHICK A, UHL W, TESCHENDORF C, WOLTERS H, STERN J, VIEBAHN R, FRIESS H, JANSSEN KP, NITSCHKE U, SLOTTA-HUSPENINA J, POHL M, VANGALA D, BARANISKIN A, DOCKHORN-DWORNICZAK B, HEGEWISCH-BECKER S, RONGA P, EDELSTEIN DL, JONES FS, HAHN S, FOX SB.
Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.
Mol Oncol. 2017 Feb;11(2):208-219. doi: 10.1002/1878-0261.12023. Epub 2017 Jan 20.
Impact Factor: 5,314

TROJAN J, KLEIN-SCORY S, KOCH C, SCHMIEGEL W, BARANISKIN A.
Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer.
Case Rep Oncol Med. 2017;2017:6139634. doi: 10.1155/2017/6139634. Epub 2017 Jan 23.
Kein Impact Factor

VAN LAETHEM JL, RIESS H, JASSEM J, HAAS M, MARTENS UM, WEEKES C, PEETERS M, ROSS P, BRIDGEWATER J, MELICHAR B, CASCINU S, SARMAK P, MICHL P, VAN BRUMMELEN D, ZANIBONI A, SCHMIEGEL W, DUELAND S, GIURESCU M, GAROSI VL, ROTH K, SCHULZ A, SEIDEL H, RAJAGOPALAN P, TEUFEL M, CHILDS BH.
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Target Oncol. 2017 Feb;12(1):97-109. doi: 10.1007/s11523-016-0469-y.
Impact Factor: 3,438

2016

AL-BATRAN SE, HOFHEINZ RD, PAULIGK C, KOPP HG, HAAG GM, LULEY KB, MEILER J, HOMANN N, LORENZEN S, SCHMALENBERG H, PROBST S, KOENIGSMANN M, EGGER M, PRASNIKAR N, CACA K, TROJAN J, MARTENS UM, BLOCK A, FISCHBACH W, MAHLBERG R, CLEMENS M, ILLERHAUS G, ZIRLIK K, BEHRINGER DM, SCHMIEGEL W, POHL M, HEIKE M, RONELLENFITSCH U, SCHULER M, BECHSTEIN WO, KÖNIGSRÄINER A, GAISER T, SCHIRMACHER P, HOZAEEL W, REICHART A, GOETZE TO, SIEVERT M, JÄGER E, MÖNIG S, TANNAPFEL A.

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.

Lancet Oncol. 2016 Dec;17(12):1697-1708. doi: 10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22

Impact Factor: 24,690

VAN LAETHEM JL, CARNEIRO F, DUCREUX M, MESSMAN H, LORDICK F, ILSON DH, ALLUM WH, HAUSTERMANS K, LEPAGE C, MATYSIAK-BUDNIK T, CATS A, SCHMIEGEL W, CERVANTES A, VAN CUTSEM E, ROUGIER P, SEUFFERLEIN T.

The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.

Dig Liver Dis. 2016 Nov;48(11):1283-1289. doi: 10.1016/j.dld.2016.08.112. Epub 2016 Aug 20

Impact Factor: 3,159

MANTENIOTIS S, WOJCIK S, BRAUHOFF P, MÖLLMANN M, PETERSEN L, GÖTHERT JR, SCHMIEGEL W, DÜHRSEN U, GISSELMANN G, HATT H.

Functional characterization of the ectopically expressed olfactory receptor 2AT4 in human myelogenous leukemia.

Cell Death Discov. 2016 Jan 25;2:15070. doi: 10.1038/cddiscovery.2015.70. eCollection 2016

Impact factor: 5,500

BRACHT T, MÖLLEKEN C, AHRENS M, POSCHMANN G, SCHLOSSER A, EISENACHER M, STÜHLER K, MEYER HE, SCHMIEGEL WH, HOLMSKOV U, SORENSEN GL, SITEK B.

Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients.

J Transl Med. 2016 Jul 4;14(1):201. doi: 10.1186/s12967-016-0952-3

Impact Factor: 3,786

Affiliation BGH

GRUENBERGER T, BEETS G, VAN LAETHEM JL, ROUGIER P, CERVANTES A, DOUILLARD JY, FIGUERAS J, GRUENBERGER B, HALLER DG, LABIANCA R, MALEUX G, ROTH A, DUCREUX M, SCHMIEGEL W, SEUFFERLEIN T, VAN CUTSEM E.

Treatment sequence of synchronously (liver) metastasized colon cancer.

Dig Liver Dis. 2016 Oct;48(10):1119-23. doi: 10.1016/j.dld.2016.06.009. Epub 2016 Jun 17. Review

Impact Factor: 3,159

MODEST DP, RICARD I, HEINEMANN V, HEGEWISCH-BECKER S, SCHMIEGEL W, PORSCHEN R, STINTZING S, GRAEVEN U, ARNOLD D, VON WEIKERSTHAL LF, GIessen-JUNG C, STAHLER A, SCHMOLL HJ, JUNG A, KIRCHNER T, TANNAPFEL A, REINACHER-SCHICK A.

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.

Ann Oncol. 2016 Sep;27(9):1746-53. doi: 10.1093/annonc/mdw261. Epub 2016 Jun 29
Impact Factor: 7,384

POHL M, SCHMIEGEL W.
Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted
Therapies in Colon Cancer Today and Tomorrow.
Dig Dis. 2016;34(5):574-9. doi: 10.1159/000445267. Epub 2016 Jun 22
Impact Factor: 2,203

POX C, SCHMIEGEL W.
Efficacy of colonoscopy screening
Z Gastroenterol. 2016 Jun;54(6):579-80. doi: 10.1055/s-0042-107878. Epub 2016 Jun 10.
German. No abstract available
Impact Factor: 1,618

MÖLLEKEN C, POSCHMANN G, BONELLA F, COSTABEL U, SITEK B, STÜHLER K, MEYER HE,
SCHMIEGEL WH, MARCUSSEN N, HELMER M, NIELSEN O, HANSEN S, SCHLOSSER A, HOLMSKOV
U, SORENSEN GL.
MFAP4: a candidate biomarker for hepatic and pulmonary fibrosis?
Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar 29;33(1):41-50.
Kein Impact Factor
Affiliation BGH

BRECHMANN T, SCHMIEGEL W, KLUTE L, RÖSCH T, POX C.
Feasibility of a colon capsule overnight procedure followed by colonoscopy.
Z Gastroenterol. 2016 Feb;54(2):146-51. doi: 10.1055/s-0041-106595. Epub 2016 Feb 8
Impact Factor: 1,618

KÖHLER J, SCHULER M, GAULER TC, NÖPEL-DÜNNEBACKE S, AHRENS M, HOFFMANN AC,
KASPER S, NENSA F, GOMEZ B, HAHNEMANN M, BREITENBUECHER F, CHEUFOU D, ÖZKAN F,
DARWICHE K, HOICZYK M, REIS H, WELTER S, EBERHARDT WE, EISENACHER M, TESCHLER H,
STAMATIS G, SCHMIEGEL W, HAHN SA, BARANISKIN A.
Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in
lung cancer patients.
J Cancer Res Clin Oncol. 2016 Apr;142(4):795-805. doi: 10.1007/s00432-015-2095-y. Epub
2015 Dec 19
Impact Factor: 3,081

VESPER I, SCHMIEGEL W, BRECHMANN T.
Equal detection rate of cervical heterotopic gastric mucosa in standard white light, high
definition and narrow band imaging endoscopy.
Z Gastroenterol. 2015 Nov;53(11):1247-54. doi: 10.1055/s-0041-104226. Epub 2015 Nov 12
Impact Factor: 1,618
Affiliation BGH

BARANISKIN A, ZASLAVSKA E, NÖPEL-DÜNNEBACKE S, AHLE G, SEIDEL S, SCHLEGEL U,
SCHMIEGEL W, HAHN S, SCHROERS R.
Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary
central nervous system lymphoma.
Neuro Oncol. 2016 Mar;18(3):361-7. doi: 10.1093/neuonc/nov144. Epub 2015 Aug 6
Impact Factor: 6,776

OLIVEIRA MC, LABOPIN M, HENES J, MOORE J, DEL PAPA N, CRAS A, SAKELLARI I, SCHROERS R,
SCHERER HU, CUNEO A, KYRCZ-KRZEMIEN S, DAIKELER T, ALEXANDER T, FINKE J, BADOGLIO M,
SIMÕES B, SNOWDEN JA, FARGE D.

Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?

Bone Marrow Transplant. 2016 Apr;51(4):501-5. doi: 10.1038/bmt.2015.299. Epub 2015 Dec

7. Erratum in: Bone Marrow Transplant. 2016 Jun;51(6):889

Kein Impact Factor

2015

BARANISKIN A, ZASLAVSKA E, NÖPEL-DÜNNEBACKE S, AHLE G, SEIDEL S, SCHLEGEL U, SCHMIEGEL W, HAHN S, SCHROERS R.
Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma.
Neuro Oncol. 2015 Aug 6.
Impact Factor: 6.776

BRECHMANN T, SCHMIEGEL W.
Successful treatment of life-threatening bleeding from a duodenal posterior bulb peptic ulcer by an over-the-scope-clip.
World J Gastroenterol. 2015 Feb 7;21(5):1666-9.
Impact Factor: 2.369
Affiliation BGH

BRECHMANN T, SWOL J, KNOP-HAMMAD V, WILLERT J, AACH M, CRUCIGER O, SCHMIEGEL W, SCHILDHAUER TA, HAMSEN U.
Complicated fecal microbiota transplantation in a tetraplegic patient with severe Clostridium difficile infection.
World J Gastroenterol. 2015 Mar 28;21(12):3736-40.
Impact Factor: 2.369
Affiliation BGH

BRENNER H, ALTENHOFEN L, KRETSCHMANN J, RÖSCH T, POX C, STOCK C, HOFFMEISTER M.
Trends in Adenoma Detection Rates During the First 10 Years of the German Screening Colonoscopy Program.
Gastroenterology. 2015 Aug;149(2):356-66.e1
Impact Factor: 16.716

CIOFFI M, TRABULO SM, SANCHEZ-RIPOLL Y, MIRANDA-LORENZO I, LONARDO E, DORADO J, REIS VIEIRA C, RAMIREZ JC, HIDALGO M, AICHER A, HAHN S, SAINZ B JR, HEESCHEN C.
The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
Gut. 2015 Dec;64(12):1936-48.
Impact Factor: 14.660

CIOFFI M, VALLESPINOS-SERRANO M, TRABULO SM, FERNANDEZ-MARCOS PJ, FIRMENT AN, VAZQUEZ BN, VIEIRA CR, MULERO F, CAMARA JA, CRONIN UP, PEREZ 8, SORIANO J, G GALVEZ B, CASTELLS-GARCIA A, HAAGE V, RAJ D, MEGIAS D, HAHN S, SERRANO L, MOON A, AICHER A, HEESCHEN C
MiR-93 Controls Adiposity via Inhibition of Sirt7 and Tbx3.
Cell Rep. 2015 Sep 8;12(10):1594-605.
Impact Factor: 8.358

EL-MASHTOLY SF, YOSEF HK, PETERSEN D, MAVARANI L, MAGHNOUJ A, HAHN S, KÖTTING C, GERWERT K.
Label-Free Raman Spectroscopic Imaging Monitors the Integral Physiologically Relevant Drug Responses in Cancer Cells.
Anal Chem. 2015 Jul 21;87(14):7297-304.
Impact Factor: 5.636

HAGEL S, EPPEL HJ, FEURLE GE, KERN WV, LYNEN JANSEN P, MALFERTHEINER P, MARTH T, MEYER E, MIELKE M, MOOS V, VON MÜLLER L, NATTERMANN J, NOTHACKER M, POX C, REISINGER E, SALZBERGER B, SALZER HJ, WEBER M, WEINKE T, SUERBAUM S, LOHSE AW, STALLMACH A; Weitere Mitglieder der Leitlinienkommission sind am Ende des Beitrags gelistet.

S2k-guideline gastrointestinal infectious diseases and Whipple's disease.

Z Gastroenterol. 2015 May;53(5):418-59.

Impact Factor: 1.053

HOZAEEL W, PAULIGK C, HOMANN N, LULEY K, THOMAS WERNER KRAUS, TROJAN J, BECHSTEIN WO, GRIMM K, HEISE B, SCHMIEGEL W, PINK D, AL-BATRAN SE

Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.

Journal of Clinical Oncology, 2015 ASCO Annual Meeting (May 29 - June 2, 2015).

Vol 33, No 15_suppl (May 20 Supplement), 2015: TPS4152

Impact Factor: 18.443

KAKKASSERY V, STÜBINGER N, ADAMIETZ IA, TISCHOFF I, BARANISKIN A, WUNDERLICH IM.

Lymphoma of the ocular adnexa.

Ophthalmologie. 2015 Mar;112(3):210-6.

Impact Factor: 0.504

KÖHLER J, SCHULER M, GAULER TC, NÖPEL-DÜNNEBACKE S, AHRENS M, HOFFMANN AC, KASPER S, NENSA F, GOMEZ B, HAHNEMANN M, BREITENBUECHER F, CHEUFOU D, ÖZKAN F, DARWICHE K, HOICZYK M, REIS H, WELTER S, EBERHARDT WE, EISENACHER M, TESCHLER H, STAMATIS G, SCHMIEGEL W, HAHN SA, BARANISKIN A.

Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.

J Cancer Res Clin Oncol. 2015 Dec 19. [Epub ahead of print]

Impact Factor: 3.081

KONG B, WU W, CHENG T, SCHLITZER AM, QIAN C, BRUNS P, JIAN Z, JÄGER C, REGEL I, RAULEFS S, BEHLER N, IRMLER M, BECKERS J, FRIESS H, ERKAN M, SIVEKE JT, TANNAPFEL A, HAHN SA, THEIS FJ, ESPOSITO I, KLEEFF J, MICHALSKI CW.

A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.

Gut. 2015 Jan 19.

Impact Factor: 14.660

KORFEL A, SCHLEGEL U, SCHROERS R.

Special hematological diagnostics and therapy options for ocular lymphoma taking CNS involvement into account.

Ophthalmologie. 2015 Mar;112(3):231-6.

Impact Factor: 0.504

LANG G, SCHMIEGEL W, NICOLAS V, BRECHMANN T.

Impact of Small Bowel MRI in Routine Clinical Practice on Staging of Crohn's Disease.

J Crohns Colitis. 2015 Sep;9(9):784-94.

Impact Factor: 6.234

Affiliation BGH

LOOSSE C, PAWLAS M, BUKHARI HS, MAGHNOUJ A, HAHN S, MARCUS K, MÜLLER T.

Nuclear spheres modulate the expression of BEST1 and GADD45G.

Cell Signal. 2016 Jan;28(1):100-9.

Impact Factor: 4.315

MAZUR PK, HERNER A, MELLO SS, WIRTH M, HAUSMANN S, SÁNCHEZ-RIVERA FJ, LOFGREN SM, KUSCHMA T, HAHN SA, VANGALA D, TRAJKOVIC-ARSIC M, GUPTA A, HEID I, NOËL PB, BRAREN R, ERKAN M, KLEEFF J, SIPOS B, SAYLES LC, HEIKENWALDER M, HEßMANN E, ELLENRIEDER V, ESPOSITO I, JACKS T, BRADNER JE, KHATRI P, SWEET-CORDERO EA, ATTARDI LD, SCHMID RM, SCHNEIDER G, SAGE J, SIVEKE JT

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

Nat Med. 2015 Oct;21(10):1163-71.

Impact Factor: 28.223

OLIVEIRA MC, LABOPIN M, HENES J, MOORE J, PAPA ND, CRAS A, SAKELLARI I, SCHROERS R, SCHERER HU, CUNEO A, KYRCZ-KRZEMIEN S, DAIKELER T, ALEXANDER T, FINKE J, BADOGLIO M, SIMÕES B, SNOWDEN JA, FARGE D.

Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?

Bone Marrow Transplant. 2015 Dec 7.

Impact Factor: 3.570

PAULIGK C, TANNAPFEL A, MEILER J, LULEY KB, KOPP HG, HOMANN N, HOFHEINZ RD, SCHMALENBERG H, PROBST S, HAAG GM, EGGER M, BEHRINGER DM, STOEHLMACHER J, PRASNIKAR N, BLOCK A, TROJAN J, KOENIGSMANN M, SCHMIEGEL W, JÄGER E, AL-BATRAN SE

Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO. Journal of Clinical Oncology, 2015 ASCO Annual Meeting (May 29 - June 2, 2015). Vol 33, No 15_suppl (May 20 Supplement), 2015: 4016

Impact Factor: 18.443

RATHMAYER M, SCHEFFER H, BRAUN M, HEINLEIN W, AKOGLU B, BRECHMANN T, GÖLDER SK, LANKISCH T, MESSMANN H, SCHNEIDER A, WAGNER M, FLEßA S, MEIER A, LEWERENZ B, GOSSNER L, FAISS S, TOERMER T, WERNER T, WILKE MH, LERCH MM, SCHEPP W; DRG-ARBEITSGRUPPE UND DAS ZEITERFASSUNGSPROJEKT DER DGVS (AUTOREN IM ANHANG).

Improvement of cost allocation in gastroenterology by introduction of a novel service catalogue covering the complete spectrum of endoscopic procedures.

Z Gastroenterol. 2015 Mar;53(3):183-98

Impact Factor: 1.052

Affiliation BGH

RÖDEL C, GRAEVEN U, FIETKAU R, HOHENBERGER W, HOTHORN T, ARNOLD D, HOFHEINZ RD, GHADIMI M, WOLFF HA, LANG-WELZENBACH M, RAAB HR, WITTEKIND C, STRÖBEL P, STAIB L, WILHELM M, GRABENBAUER GG, HOFFMANNS H, LINDEMANN F, SCHLENSKA-LANGE A, FOLPRECHT G, SAUER R, LIERSCH T; GERMAN RECTAL CANCER STUDY GROUP.

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.

Lancet Oncol. 2015 Aug;16(8):979-89.

Impact Factor: 24.690

VANGALA DB, LIFFERS ST, POHL M, TESCHENDORF C, TANNAPFEL A, SCHMIEGEL W, HAHN SA

Effect of Sym004 on acquired resistance to cetuximab in colorectal cancer (CRC) in a novel mouse avatar model.

Journal of Clinical Oncology, 2015 ASCO Annual Meeting (May 29 - June 2, 2015).

Vol 33, No 15_suppl (May 20 Supplement), 2015: 3578

Impact Factor: 18.443

VESPER I, SCHMIEGEL W, BRECHMANN T.

Equal detection rate of cervical heterotopic gastric mucosa in standard white light, high definition and narrow band imaging endoscopy.

Z Gastroenterol. 2015 Nov;53(11):1247-1254. Epub 2015 Nov 12.

Impact Factor: 1.052

Affiliation BGH

YOSEF HK, MAVARANI L, MAGHNOUJ A, HAHN S, EL-MASHTOLY SF, GERWERT K.

In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging.

Anal Bioanal Chem. 2015 Nov;407(27):8321-31.

Impact Factor: 3.436

2014

BARANISKIN A, NÖPEL-DÜNNEBACKE S, SCHUMACHER B, GERGES C, BRACHT T, SITEK B, MEYER HE, GERKEN G, DECHENE A, SCHLAAK JF, SCHROERS R, POX C, SCHMIEGEL W, HAHN SA.
Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.
Dig Dis Sci. 2014 Jul;59(7):1436-41. doi: 10.1007/s10620-014-3034-5. Epub 2014 Jan 31.
Impact Factor: 2,550

BARANISKIN A, SCHROERS R.
Modern cerebrospinal fluid analyses for the diagnosis of diffuse large B-cell lymphoma of the CNS.
CNS Oncol. 2014 Jan;3(1):77-85. doi: 10.2217/cns.13.63.
Kein Impact Factor

DAYEM ULLAH AZ, CUTTS RJ, GHETIA M, GADALETA E, HAHN SA, CRNOGORAC-JURCEVIC T, LEMOINE NR, CHELALA C.
The pancreatic expression database: recent extensions and updates. Nucleic Acids Res. 2014 Jan 1;42(1):D944-9. doi: 10.1093/nar/gkt959. Epub 2013 Oct 25.
Impact Factor: 11,561

KLEIN-SCORY S, TEHRANI MM, EILERT-MICUS C, ADAMCZYK KA, WOJTALEWICZ N, SCHNÖLZER M, HAHN SA, SCHMIEGEL W, SCHWARTE-WALDHOFF I.
New insights in the composition of extracellular vesicles from pancreatic cancer cells: implications for biomarkers and functions.
Proteome Sci. 2014 Nov 18;12(1):50. doi: 10.1186/s12953-014-0050-5. eCollection 2014.
Impact Factor:1,878

KUHLMANN JD, BARANISKIN A, HAHN SA, MOSEL F, BREDEMEIER M, WIMBERGER P, KIMMIG R, KASIMIR-BAUER S.
Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer.
Clin Chem. 2014 Jan;60(1):206-13. doi: 10.1373/clinchem.2013.213066. Epub 2013 Nov 8.
Impact Factor: 8,008

NÖPEL-DÜNNEBACKE S, SCHULMANN K, REINACHER-SCHICK A, PORSCHEN R, SCHMIEGEL W, TANNAPFEL A, GRAEVEN U
Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Z Gastroenterol. 2014 Dec;52(12):1394-1401. Epub 2014 Dec 4.
Impact Factor: 1,671

POX CP, SCHMIEGEL W.
[Colorectal cancer].
Dtsch Med Wochenschr. 2014 Jan;139(5):193-202; quiz 203-6. doi: 10.1055/s-0033-1359874. Epub 2014 Jan 21. Review. German. No abstract available.
Impact Factor: 0,550

POX CP, SCHMIEGEL W.
[German S3-guideline colorectal carcinoma].
Dtsch Med Wochenschr. 2013 Dec;138(49):2545. doi: 10.1055/s-0033-1353953. Epub 2013 Nov 26. German. No abstract available.
Impact Factor: 0,550

PROETEL U, PLETSCH N, LAUSEKER M, MÜLLER MC, HANFSTEIN B, KRAUSE SW, KALMANTI L, SCHREIBER A, HEIM D, BAERLOCHER GM, HOFMANN WK, LANGE E, EINSELE H, WERNLI M, KREMERS S, SCHLAG R, MÜLLER L, HÄNEL M, LINK H, HERTENSTEIN B, PFIRMAN M, HOCHHAUS A, HASFORD J, HEHLMANN R, SAUßELE S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).

Older patients with chronic myeloid leukemia (≥ 65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.

Ann Hematol. 2014 Jul;93(7):1167-76.

Impact Factor: 2.634

STEINKE V, HOLZAPFEL S, LOEFFLER M, HOLINSKI-FEDER E, MORAK M, SCHACKERT HK, GÖRGENS H, POX C, ROYER-POKORA B, VON KNEBEL-DOEBERITZ M, BÜTTNER R, PROPPING P, ENGEL C, GERMAN HNPCC CONSORTIUM.

Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families.

Int J Cancer. 2014 Jul 1;135(1):69-77. doi: 10.1002/ijc.28650. Epub 2014 Feb 20.

Impact Factor: 5,007

SEUFFERLEIN T, PORZNER M, BECKER T, BUDACH V, CEYHAN G, ESPOSITO I, FIETKAU R, FOLLMANN M, FRIESS H, GALLE P, GEIßLER M, GLANEMANN M, GRESS T, HEINEMANN V, HOHENBERGER W, HOPT U, IZBICKI J, KLAR E, KLEEFF J, KOPP I, KULLMANN F, LANGER T, LANGREHR J, LERCH M, LÖHR M, LÜTTGES J, LUTZ M, MAYERLE J, MICHL P, MÖLLER P, MOLLS M, MÜNTER M, NOTHACKER M, OETTLE H, POST S, REINACHER-SCHICK A, RÖCKEN C, ROEB E, SAEGER H, SCHMID R, SCHMIEGEL W, SCHOENBERG M, SIVEKE J, STUSCHKE M, TANNAPFEL A, UHL W, UNVERZAGT S, VAN OORSCHOT B, VASHIST Y, WERNER J, YEKEBAS E; GUIDELINES PROGRAMME ONCOLOGY AWMF; GERMAN CANCER SOCIETY EV; GERMAN CANCER AID. [S3-guideline exocrine pancreatic cancer].

Z Gastroenterol. 2013 Dec;51(12):1395-440. doi: 10.1055/s-0033-1356220. Epub 2013 Dec 11. German. No abstract available.

Impact Factor: 1,671

VAN LAAR JM, FARGE D, SONT JK, NARAGHI K, MARJANOVIC Z, LARGHERO J, SCHUERWEGH AJ, MARIJT EW, VONK MC, SCHATTENBERG AV, MATUCCI-CERINIC M, VOSKUYL AE, VAN DE LOOSDRECHT AA, DAIKELER T, KÖTTER I, SCHMALZING M, MARTIN T, LIOURE B, WEINER SM, KREUTER A, DELIGNY C, DURAND JM, EMERY P, MACHOLD KP, SARROT-REYNAULD F, WARNATZ K, ADOUE DF, CONSTANS J, TONY HP, DEL PAPA N, FASSAS A, HIMSEL A, LAUNAY D, LO MONACO A, PHILIPPE P, QUÉRÉ I, RICH É, WESTHOVENS R, GRIFFITHS B, SACCARDI R, VAN DEN HOOGEN FH, FIBBE WE, SOCIÉ G, GRATWOHL A, TYNDALL A; EBMT/EULAR SCLERODERMA STUDY GROUP.

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.

JAMA. 2014 Jun 25;311(24):2490-8. doi: 10.1001/jama.2014.6368.

Kein Impact Factor

WIEGAND J, WEDEMEYER H, FRANKE A, RÖßLER S, ZEUZEM S, TEUBER G, WÄCHTLER M, RÖMMELE U, RUF B, SPENGLER U, TRAUTWEIN C, BOCK CT, FIEDLER GM, THIERY J, MANNS MP, BROSTEANU O, TILLMANN HL; GERMAN HEP-NET ACUTE HEPATITIS B (GAHB) STUDY GROUP.

Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial.

J Viral Hepat. 2014 Oct;21(10):744-50. doi: 10.1111/jvh.12210. Epub 2013 Dec 11.

Impact Factor: 3,307

WOJTALEWICZ N, SADEQZADEH E, WEIß JV, TEHRANI MM, KLEIN-SCORY S, HAHN S, SCHMIEGEL W, WARNKEN U, SCHNÖLZER M, DE BOCK CE, THORNE RF, SCHWARTE-WALDHOFF I.

A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding.
PLoS One. 2014 Mar 13;9(3):e90461. doi: 10.1371/journal.pone.0090461. eCollection 2014.
Impact Factor: 3,534

YANG R, CHEN B, PFÜTZE K, BUCH S, STEINKE V, HOLINSKI-FEDER E, STÖCKER S, VON SCHÖNFELS W, BECKER T, SCHACKERT HK, ROYER-POKORA B, KLOOR M, SCHMIEGEL WH, BÜTTNER R, ENGEL C, LASCORZ PUERTOLAS J, FÖRSTI A, KUNKEL N, BUGERT P, SCHREIBER S, KRAWCZAK M, SCHAFMAYER C, PROPPING P, HAMPE J, HEMMINKI K, BURWINKEL B.
Genome-wide analysis associates familial colorectal cancer with increases in copy number variations and a rare structural variation at 12p12.3.
Carcinogenesis. 2014 Feb;35(2):315-23. doi: 10.1093/carcin/bgt344. Epub 2013 Oct 14.
Impact Factor: 5,266

ZÖLLNER H, HAHN SA, MAGHNOUJ A.
Lentiviral overexpression of miRNAs. Methods Mol Biol. 2014;1095:177-90. doi: 10.1007/978-1-62703-703-7_15.
Kein Impact Factor

ZÖLLNER H, HAHN SA, MAGHNOUJ A.
Quantitative RT-PCR specific for precursor and mature miRNAs. Methods Mol Biol. 2014;1095:121-34. doi: 10.1007/978-1-62703-703-7_10.
Kein Impact Factor

2013

BARANISKIN A, NÖPEL-DÜNNEBACKE S, AHRENS M, JENSEN SG, ZÖLLNER H, MAGHNOUJ A, WOS A, MAYERLE J, MUNDING J, KOST D, REINACHER-SCHICK A, LIFFERS S, SCHROERS R, CHROMIK AM, MEYER HE, UHL W, KLEIN-SCORY S, WEISS FU, STEPHAN C, SCHWARTE-WALDHOFF I, LERCH MM, TANNAPFEL A, SCHMIEGEL W, ANDERSEN CL, HAHN SA
Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma.
Int J Cancer. 2013 Jan 15;132(2):E48-57. doi: 10.1002/ijc.27791. Epub 2012 Sep 14.
Impact Factor: 6,198

BARANISKIN A, SCHROERS R
Emergencies in hematology and oncology.
Inn Med up 2013; 01(02):89-102
Kein Impact-Factor

BARANISKIN A, STEFFENS C, HARDERS A, SCHMIEGEL W, SCHROERS R, SPANGENBERG P
Impact of Pre-Hospital Antithrombotic Medication on the Outcome of Chronic and Acute Subdural Hematoma.
J Neurol Surg A Cent Eur Neurosurg. 2013 Feb 20. [Epub ahead of print]
Impact Factor: 3,578

BENNOUNA J, SASTRE J, ARNOLD D, ÖSTERLUND P, GREIL R, VAN CUTSEM E, VON MOOS R, VIÉITEZ JM, BOUCHÉ O, BORG C, STEFFENS CC, ALONSO-ORDUÑA V, SCHLICHTING C, REYES-RIVERA I, BENDAHMANE B, ANDRÉ T, KUBICKA S; ML18147 STUDY INVESTIGATORS
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1.
Epub 2012 Nov 16.
Impact Factor: 25,117

BIRKENKAMP-DEMTRÖDER K, HAHN SA, MANSILLA F, THORSEN K, MAGHNOUJ A, CHRISTENSEN R, ØSTER B, ØRNTTOFT TF
Keratin23 (KRT23) knockdown decreases proliferation and affects the DNA damage response of colon cancer cells.
PLoS One. 2013 Sep 9;8(9):e73593. doi: 10.1371/journal.pone.0073593.
Impact Factor: 3,730

BRAND L, MUNDING J, POX CP, ZIEBARTH W, REISER M, HÜPPE D, SCHMIEGEL W, REINACHER-SCHICK A, TANNAPFEL A
β-catenin, Cox-2 and p53 immunostaining in colorectal adenomas to predict recurrence after endoscopic polypectomy.
Int J Colorectal Dis. 2013 Aug;28(8):1091-8. doi: 10.1007/s00384-013-1667-z. Epub 2013 Mar 21.
Impact Factor: 2,238

BRENNER H, KLOOR M, POX CP
Colorectal cancer.
Lancet. 2013 Nov 8. pii: s0140-6736(13)61649-9. doi: 10.1016/s0140-6736(13)61649-9 [Epub ahead of print]
Impact Factor: 39,060

BUDNIAK L, SCHMIEGEL W, POX C
83-year-old patient with salmonella bacteremia and infection-associated Sweet's syndrome.
Dtsch Med Wochenschr. 2013 Jan;138(4):126-8. doi: 10.1055/s-0032-1332847. Epub 2013 Jan 15. German.
Impact Factor: 0,653

DAYEM ULLAH AZ, CUTTS RJ, GHETIA M, GADALETA E, HAHN SA, CRNOGORAC-JURCEVIC T, LEMOINE NR, CHELALA C
The pancreatic expression database: recent extensions and updates.
Nucleic Acids Res. 2014 Jan 1;42(1):D944-9. doi: 10.1093/nar/gkt959. Epub 2013 Oct 25.
Impact Factor: 8,278

EUROPEAN COLORECTAL CANCER SCREENING GUIDELINES WORKING GROUP, VON KARSA L, PATNICK J, SEGNAV N, ATKIN W, HALLORAN S, LANSDORP-VOGELAAR I, MALILA N, MINOZZI S, MOSS S, QUIRKE P, STEELE RJ, VIETH M, AABAKKEN L, ALTENHOFEN L, ANCELLE-PARK R, ANTOLJAK N, ANTTILA A, ARMAROLI P, ARROSSI S, AUSTOKER J, BANZI R, BELLISARIO C, BLOM J, BRENNER H, BRETTHAUER M, CAMARGO CANCELA M, COSTAMAGNA G, CUZICK J, DAI M, DANIEL J, DEKKER E, DELICATA N, DUCARROZ S, ERFKAMP H, ESPINÀS JA, FAIVRE J, FAULDS WOOD L, FLUGELMAN A, FRKOVIC-GRAZIO S, GELLER B, GIORDANO L, GRAZZINI G, GREEN J, HAMASHIMA C, HERRMANN C, HEWITSON P, HOFF G, HOLTEN I, JOVER R, KAMINSKI MF, KUIPERS EJ, KURTINAITIS J, LAMBERT R, LAUNOY G, LEE W, LEICESTER R, LEJA M, LIEBERMAN D, LIGNINI T, LUCAS E, LYNGE E, MÁDAI S, MARINHO J, MAUČEC ZAKOTNIK J, MINOLI G, MONK C, MORAIS A, MUWONGE R, NADEL M, NEAMTIU L, PERIS TUSER M, PIGNONE M, POX C, PRIMIC-ZAKELJ M, PSAILA J, RABENECK L, RANSOHOFF D, RASMUSSEN M, REGULA J, REN J, RENNERT G, REY J, RIDDELL RH, RISIO M, RODRIGUES V, SAITO H, SAUVAGET C, SCHARPANTGEN A, SCHMIEGEL W, SENORE C, SIDDIQI M, SIGHOKO D, SMITH R, SMITH S, SUCHANEK S, SUONIO E, TONG W, TÖRNBERG S, VAN CUTSEM E, VIGNATELLI L, VILLAIN P, VOTI L, WATANABE H, WATSON J, WINAWER S, YOUNG G, ZAKSAS V, ZAPPA M, VALORI R
European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication.

Endoscopy. 2013;45(1):51-9. doi: 10.1055/s-0032-1325997. Epub 2012 Dec 4.
Impact Factor: 5,735

GIESSEN C, GRAEVEN U, LAUBENDER RP, MODEST DP, SCHULZ C, PORSCHEN R, SCHMIEGEL W, REINACHER-SCHICK A, HEGEWISCH-BECKER S, STINTZING S, HEINEMANN V
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
Ann Oncol. 2013 Dec;30:51-5. doi: 10.1093/annonc/mdt402. Epub 2013 Oct 14.
Impact Factor: 7,384

HASSAN C, QUINTERO E, DUMONCEAU JM, REGULA J, BRANDAO C, CHAUSSADE S, DEKKER E, DINIS-RIBEIRO M, FERLITSCH M, GIMENO-GARCIA A, HAZEWINDEL Y, JOVER R, KALAGER M, LOBERG M, POX C, REMBACKEN B, LIEBERMANN D
Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
Endoscopy. 2013 Oct;45(10):842-51. doi: 10.1055/s-0033-1344548.
Impact Factor: 5,735

HERMANN PC, TRABULO SM, SAINZ B JR, BALIC A, GARCIA E, HAHN SA, VANDANA M, SAHOO SK, TUNICI P, BAKKER A, HIDALGO M, HEESCHEN C
Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts.
PLoS One. 2013 Jun 18;8(6):e66371. Print 2013.
Impact Factor: 3,730

KORFEL A, ELTER T, THIEL E, HÄNEL M, MÖHLE R, SCHROERS R, REISER M, DREYLING M, EUCKER J, SCHOLZ C, METZNER B, RÖTH A, BIRKMANN J, SCHLEGEL U, MARTUS P, ILLERHAUS G, FISCHER L
Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas.
Haematologica. 2013 Mar;98(3):364-70. doi: 10.3324/haematol.2012.077917. Epub 2012 Dec 14.
Impact Factor: 5,935

KUBICKA S, GREIL R, ANDRÉ T, BENNOUNA J, SASTRE J, VAN CUTSEM E, VON MOOS R, OSTERLUND P, REYES-RIVERA I, MÜLLER T, MAKRUTZKI M, ARNOLD D; ML18147 STUDY INVESTIGATORS INCLUDING AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, AND AGMT GROUPS.
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
Ann Oncol. 2013 Sep;24(9):2342-9. doi: 10.1093/annonc/mdt231.
Impact Factor: 7,384

KUHLMANN JD, BARANISKIN A, HAHN SA, MOSEL F, BREDEMEIER M, WIMBERGER P, KIMMIG R, KASIMIR-BAUER S
Circulating u2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer.
Clin Chem. 2014 Jan;60(1):206-13. doi: 10.1373/clinchem.2013.213066. Epub 2013 Nov 8.
Impact Factor: 7,149

POHL M, SCHMIEGEL W
Colorectal cancer - personalized, stage-adjusted tumour therapy.

Dtsch Med Wochenschr. 2013 Sep;138(36):1790-5. doi: 10.1055/s-0033-1343343. Epub 2013 Sep 3. Review. German.
Impact Factor: 0,653

POX C, ARETZ S, BISCHOFF SC, GRAEVEN U, HASS M, HEUßNER P, HOHENBERGER W, HOLSTEGE A, HÜBNER J, KOLLIGS F, KREIS M, LUX P, OCKENGA J, PORSCHEN R, POST S, RAHNER N, REINACHER-SCHICK A, RIEMANN JF, SAUER R, SIEG A, SCHEPPACH W, SCHMITT W, SCHMOLL HJ, SCHULMANN K, TANNAPFEL A, SCHMIEGEL W
S3-guideline colorectal cancer version 1.0.
Z Gastroenterol. 2013 Aug;51(8):753-854. doi: 10.1055/s-0033-1350264. Epub 2013 Aug 16. German. No abstract available.
Impact Factor: 1,408

POX CP, SCHMIEGEL W
German s3-guideline colorectal carcinoma.
Dtsch Med Wochenschr. 2013 Dec;138(49):2545. doi: 10.1055/s-0033-1353953. Epub 2013 Nov 26.
Impact Factor: 0,653

SAND M, SKRYGAN M, SAND D, GEORGAS D, GAMBICHLER T, HAHN SA, ALTMAYER P, BECHARA FG
Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi.
Cell Tissue Res. 2013 Jan;351(1):85-98. doi: 10.1007/s00441-012-1514-5. Epub 2012 Oct 31.
Impact Factor: 3,677

SCHMIEGEL W, REINACHER-SCHICK A, ARNOLD D, KUBICKA S, FREIER W, DIETRICH G, GEISLER M, HEGEWISCH-BECKER S, TANNAPFEL A, POHL M, HINKE A, SCHMOLL HJ, GRAEVEN U
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Ann Oncol. 2013 Jun;24(6):1580-7. doi: 10.1093/annonc/mdt028. Epub 2013 Mar 4.
Impact Factor: 7,384

SEUFFERLEIN T, PORZNER M, BECKER T, BUDACH V, CEYHAN G, ESPOSITO I, FIETKAU R, FOLLMANN M, FRIESS H, GALLE P, GEISLER M, GLANEMANN M, GRESS T, HEINEMANN V, HOHENBERGER W, HOPT U, IZBICKI J, KLAR E, KLEEFF J, KOPP I, KULLMANN F, LANGER T, LANGREHR J, LERCH M, LÖHR M, LÜTTGES J, LUTZ M, MAYERLE J, MICHL P, MÖLLER P, MOLLS M, MÜNTER M, NOTHACKER M, OETTLE H, POST S, REINACHER-SCHICK A, RÖCKEN C, ROEB E, SAEGER H, SCHMID R, SCHMIEGEL W, SCHOENBERG M, SIVEKE J, STUSCHKE M, TANNAPFEL A, UHL W, UNVERZAGT S, VAN OORSCHOT B, VASHIST Y, WERNER J, YEKEBAS
S3-guideline exocrine pancreatic cancer.
Z Gastroenterol. 2013 Dec;51(12):1395-440. doi: 10.1055/s-0033-1356220. Epub 2013 Dec 11.
Impact Factor: 1,408

STEINKE V, ENGEL C, BÜTTNER R, SCHACKERT HK, SCHMIEGEL WH, PROPPING P
Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome.
Dtsch Arztebl Int. 2013 Jan;110(3):32-8. doi: 10.3238/arztebl.2013.0032. Epub 2013 Jan 18. Review.
Impact Factor: 3,945

STEINKE V, PROPPING P, ENGEL C, BÜTTNER R, SCHACKERT K, SCHMIEGEL WH

Correspondence (reply): In reply.

Dtsch Arztebl Int. 2013 May;110(20):364. doi: 10.3238/arztebl.2013.0364b. No abstract available.

Impact Factor: 3,945

STOCK AM, POWE DG, HAHN SA, TROOST G, NIGGEMANN B, ZÄNKER KS, ENTSCHLADEN F

Norepinephrine inhibits the migratory activity of pancreatic cancer cells.

Exp Cell Res. 2013 Jul 15;319(12):1744-58. doi: 10.1016/j.yexcr.2013.04.015. Epub 2013 Apr 29.

Impact Factor: 3,557

VANGALA DB, SCHMIEGEL W, POX CP

Dyspnea and weight loss in a 70-year-old man.

Internist (Berl). 2013 Jul;54(7):880-3. doi: 10.1007/s00108-013-3298-4. German.

Impact Factor: 0,329

VOGL TJ, SCHMIEGEL W, POX C, PEREIRA PL, BRAMBS HJ, LUX P, FISCHER S; GERMAN SOCIETY FOR DIGESTIVE AND METABOLIC DISEASES

S3 guideline--Diagnosis and treatment of colorectal carcinoma: relevance for radiologic imaging and interventions.

Rofo. 2013 Aug;185(8):699-708. doi: 10.1055/s-0033-1335818. Epub 2013 Jun 26. German.

Kein Impact Factor

YANG R, CHEN B, PFÜTZE K, BUCH S, STEINKE V, HOLINSKI-FEDER E, STÖCKER S, VON SCHÖNFELS W, BECKER T, SCHACKERT HK, ROYER-POKORA B, KLOOR M, SCHMIEGEL WH, BÜTTNER R, ENGEL C, LASCORZ PUERTOLAS J, FÖRSTI A, KUNKEL N, BUGERT P, SCHREIBER S, KRAWCZAK M, SCHAFMAYER C, PROPPING P, HAMPE J, HEMMINKI K, BURWINKEL B

Genome-wide analysis associates familial colorectal cancer with increases in copy number variations and a rare structural variation at 12p12.3.

Carcinogenesis. 2013 Nov 16. [Epub ahead of print]

Impact Factor: 5,635

ZIMMERMANN G, PAPKE B, ISMAIL S, VARTAK N, CHANDRA A, HOFFMANN M, HAHN SA, TRIOLA G, WITTINGHOFFER A, BASTIAENS PI, WALDMANN H

Small molecule inhibition of the KRAS-PDE δ interaction impairs oncogenic KRAS signalling.

Nature. 2013 May 30;497(7451):638-42. doi: 10.1038/nature12205.

Impact Factor: 38,597

ZÖLLNER H, HAHN SA, MAGHNOUJ A

Lentiviral overexpression of miRNAs.

Methods Mol Biol. 2014;1095:177-90. doi: 10.1007/978-1-62703-703-7_15.

Kein Impact Factor

ZÖLLNER H, HAHN SA, MAGHNOUJ A

Quantitative RT-PCR specific for precursor and mature miRNAs.

Methods Mol Biol. 2014;1095:121-34. doi: 10.1007/978-1-62703-703-7_10.

Kein Impact Factor

Publikationen Prof. Dr. med. Uwe Schlegel (ab 1986, Stand 20. August 2018)

Von Baumgarten L, Illerhaus G, Korfel A, **Schlegel U**, Deckert M, Dreyling M. The diagnosis and treatment of Primary CNS Lymphoma. Dtsch. Ärzteblatt 2018;115: 419 - 426

Grönheit W, Popkirov S, Wehner T, **Schlegel U**, Wellmer J. Practical management of epileptic seizures and status epilepticus in adult palliative care patients. Front. Neurol. 2018;9:595. doi:10.3389/fneur.2018.00595

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, **Schlegel U**, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex d, Belka C, Vatter H, Proeschold M, Herrlinger U, Glas M. Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. J Cancer Clin Oncol. 2018; 144:1581 - 1589

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, **Schlegel U**, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol 2018;20: 975 - 985

Popkirov S, Jungilligens J, **Schlegel U**, Wellmer J. Research on dissociative seizure: A bibliometric analysis and visualization of the scientific landscape. Epilepsy Behav. 2018;83: 162 - 167

Popkirov S, Flasbeck V, **Schlegel U**, Juckel G, Brüne M. Alexithymia in borderline personality disorder is not associated with deficits in automatic visual processing of negative emotional stimuli. Psychiatry Res. 2018;263: 121 – 124

Popkirov S, Flasbeck V, **Schlegel U**, Juckel G, Brüne M. Childhood trauma and dissociative symptoms predict frontal EEG asymmetry in borderline personality disorder. J Trauma Dis-sociation 2018;15: 1 - 16

Baraniskin A, Chomiak M, Ahle G, Gress T, Buchholz M, Turewicz M, Eisenacher M, Margold M, **Schlegel U**, Schmiegel W, Hahn S, Schroers R. Micro-RNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS. J Neurooncol. 2018;137: 463 - 468

Dagmar D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, **Schlegel U**, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P. Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medullablastoma (NOA-07). Neuro Oncol. 2018;20: 400 - 410

Kowalski C, Graeven U, von Kalle C, Lang H, Beckmann MW, Blohmer JU, Burchardt M, Ehrenfeld M, Fichtner J, Grabbe S, Hoffman H, Iro H, Post S, Scharl A, **Schlegel U**, Seufferlein T, Stummer W, Ukena D, Ferencz J, Wesselmann S. Shifting cancer care towards multidisciplinary: the cancer center certification program of the German cancer center society. *BMC Cancer* 2017;17: 850

Waldera-Lupa DM, Etemad-Parishanzadeh O, Brocksieper M, Kirchgaessler N, Seidel S, Kowalski T, Montesinos-Rongen M, Deckert M, **Schlegel U**, Stühler K. Proteomic changes in cerebrospinal fluid from primary central nervous system lymphoma patients are associated with protein ectodomain shedding. *Oncotarget*. 2017;8

Popkirov S, Ayzenberg I, Hahn S, Bauer J, Denno Y, Rieckhoff N, Radzimski C, Hans VH, Berg S, Roghmann F, Noldus J, Bien CG, Skodda S, Wellmer J, Stöcker W, Krogias C, Gold R, **Schlegel U**, Probst C, Komorowski L, Miske R, Kleiter I. Rho-associated protein kinase 2 (ROCK2): a new target of autoimmunity in paraneoplastic encephalitis. *Acta Neuropathol. Commun* 2017;5: 40

Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, Tonn JC, Westphal M, Sabel M, **Schlegel U**, Wick W, Pietsch T, Reifenberger G, Loeffler M, Bendszus M, Weller M. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. *Neurology* 2017;88: 1422 – 1430

Kakkassery V, Schroers R, Coupland SE, Wunderlich MI, Schargus M, Heinz C, Wasmuth S, Heiligenhaus A, Ahle G, Lenoble P, **Schlegel U**, Schmiegel W, Dick HB, Baraniskin A. Vitreous microRNA levels as diagnostic biomarkers for vitreo-retinal lymphoma. *Blood* 2017;129: 3130 - 3133

Ismail SF, **Schlegel U**, Kowoll A, Skodda S. Episodic central hypopnea and hypotension: Caused by bleeding into a craniocervical ependymoma. *Nervenarzt* 2017;[Epub ahead of print].

Ismail FS, Enzi B, Boy C, Kowoll A, Eyding J, **Schlegel U**. Relapsing polychondritis as an unusual cause of multiple cranial nerve palsies – a case report. *Muscle Nerve* 2017;56: E3 – E4

Schlegel U, Korfel A. The challenge of adequate imaging surveillance in primary central nervous system lymphoma. *Neuro Oncol*. 2017;19: 307 - 308

Geisler T, Poli S, Meisner C, Schrieck J, Zuern CS, Nägele T, Brachmann J, Jung W, Gahn G, Schmid E, Bäezner H, Keller T, Petzold GC, Schrickel JW, Liman J, Wachter R, Schön F, Schabet M, Lindner A, Ludolph AC, Kimmig H, Jander S, **Schlegel U**, Gawaz M, Ziemann U. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. *Int J Stroke* 2017;12: 985 - 990

Strehlow F, Bauer S, Martus P, Weller M, Roth P, **Schlegel U**, Seidel S, Scheibenbogen C, Korfel A, Kreher S. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. *J Neurooncol* 2016;126: 165 - 171

Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnala S, Dai C, Ozawa T, Chang M, Chan TA, Beal K, Bishop AJ, Baker CA, Jones TS, Hentschel B, Gorlia T, **Schlegel U**, Stupp R, Weller M, Holland EC, Hambardzumyan D. Corticosteroids compromise survival in glioblastoma. *Brain* 2016;139: 1458 - 1471

Korfel A, Chamberlain M, Neuwelt E, Thiel E, Doolittle N, **Schlegel U**, Dreyling M, Rubenstein J, Fischer L, Björkholm M, Martus P, Weller M, Glantz M. Therapy for secondary CNS involvement in malignant lymphomas: No standard yet! *J Clin Oncol* 2016;34: 1829 - 1830

Korfel A, **Schlegel U**, Herrlinger U, Dreyerling M, Schmidt C, von Baumgarten L, Pezzutto A, Grobosch T, Kebir S, Thiel E, Martus P, Kiewe P. Phase II Trial of Temsirolimus for relapsed/refractory Primary CNS Lymphoma. *J Clin Oncol*. 2016;34: 1757 - 1763

Latzer P, **Schlegel U**, Theiss C. Morphological changes of cortical and hippocampal Neurons after treatment with VEGF and Bevacizumab. *CNS Neurosci Ther*. 2016;22: 440 - 450

Popkirov S, **Schlegel U**, Skodda S. Is postoperative encephalopathy with choreoathetosis an acquired form of neurocanthocytosis? *Med Hypotheses* 2016;89: 21 -23

Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, **Schlegel U**, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M. Bevacizumab plus Irinotecan versus Temozolomide in newly diagnosed 06-Methylguanine-DNA Methyltransferase nonmethylated Glioblastoma: The randomized GLARIUS Trial. *J Clin Oncol*. 2016;34: 1611 - 1619

Popkirov S, Figge A, **Schlegel U**, Skodda S. Tertiary hyperparathyroidism presenting as posterior reversible encephalopathy syndrome. *Neurology* 2016;86: 695 - 696

Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, **Schlegel U**, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HG. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR Trial. *Neuro Oncol*. 2016;18: 549 - 556

Baraniskin A, Zaslava E, Nöpel-Dünnebacke S, Ahle G, Seidel S, Schlegel U, Schmiegel W, Hahn S, Schroers R. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma. *Neuro Oncol*. 2016,18: 361 - 367

Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel M, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HG. 136 Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma results from the DIRECTOR Trail. *Neurosurgery* 2015;62 suppl 1:209

Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, **Schlegel U**, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffiatti R, Weller M; European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. *Lancet Oncol.* 2015;16: e322 - 332

Lang N, Esser W, Evers S, Kellinghaus C, Nguento A, **Schlegel U**, Gaida B, Gburek-Augustat J, Altenmüller DM, Burghaus L, Hoffmann F, Fiedler B, Bast T, Rehfeld T, Happe S, Seitz RJ, Boor R, Stephani U. Intravenous levetiracetam in clinical practise – Results from an independent registry. *Seizure* 2015;29: 109 - 113

Korfel A, **Schlegel U**. Primary CNS lymphoma: Progress in the diagnostics and therapy. *Nervenarzt* 2015;86: 710 - 715

Popkirov S, Kowalski T, **Schlegel U**, Skodda S. Immunoglobulin-G4-related hypertrophic pachymeningitis with antineutrophil cytoplasmatic antibodies effectively treated with rituximab. *J Clin Neurosci.* 2015;22: 1038 – 1040

Weller M, Weber RG, Willscher E, Rieher V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, **Schlegel U**, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. *Acta Neuropathol.* 2015;129: 679 - 693

Korfel A, **Schlegel U**, Schroers R. Special hematological diagnostics and therapy options for ocular lymphoma taking CNS involvement into account. *Ophthalmologie* 2015;112: 231 - 236

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabe MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, **Schlegel U**, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W. MGMT promotor methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. *Clin Cancer Res.* 2015;21: 2057 -2064

Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, **Schlegel U**, Senft C, Geletneky K, Braun C, Hartung JG, Reuter D, Metz MW, Bach F, Pietsch T. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. *Eur J Cancer* 2015;51: 522 - 532

Rusz J, Saft C, **Schlegel U**, Hoffmann R, Skodda S. Phonatory dysfunction as a preclinical symptom of Huntington disease. PLoS One 2014;9(11): e113412

Tabatabai G, Hattingen E, Schlegel J, Stummer W, **Schlegel U**. Interdisciplinary neuro-oncology: Part 2: systemic therapy of primary brain tumors. Nervenarzt 2014;85: 976 – 981

Tabatabai G, Hattingen E, Schlegel J, Stummer W, **Schlegel U**. Interdisciplinary neuro-oncology Part 1: diagnostics and operative therapy of primary brain tumors. Nervenarzt 2014;85: 965 -975

Sanna T, Diener HC, Passmann RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Beckers F, Lindborg K, Brachmann J; Crystal AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370: 2478 - 2486

Popkirov S, Grönheit W, **Schlegel U**, Wellmer J. Recurrent loss of consciousness despite DDD pacing: psychogenic pseudosyncope in a 19-year-old man. Clin Res Cardiol. 2014; 103: 755 - 757

Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, Gietzelt J, Hentschel B, Westphal M, Simon M, Schackert G, Schramm J, Matschke J, Sabel MC, Gramatzki D, Felsberg J, Hartmann C, Steinbach JP, **Schlegel U**, Wick W, Radlwimmer B, Pietsch T, Tonn JC, von Deimling A, Binder H, Weller M, Loeffler M; for the German Glioma Network. Molecular characterization of long-term survivors of glioblastoma using genome-and transcriptome-wide profiling. Int J Cancer 2014;135: 1822 - 1831

Skodda S, **Schlegel U**, Hoffmann R, Saft C. Impaired motor speech performance in Huntington`s disease. J Neurol Transm. 2014;121: 399 - 407

Eisele G, Wick A, Eisele AC, Clément PM, Tonn J, Tabatabai G, Ochsenbein A, **Schlegel U**, Neyns B, Krex D, Simon M, Nikkhah G, Picard M, Stupp R, Wick W, Weller M. Cilengitide treatment of newly diagnoses glioblastoma patients does not alter patterns of progression. J Neurooncol 2014;117: 141 - 145

Skodda S, Grönheit W, **Schlegel U**, Südmeyer M, Schnitzler A, Wojtecki L. Effect of sub-thalamic stimulation on voice and speech in Parkinson`s disease: for the better or worse? Front Neurol. 2014;4: 218

Heese O, Vogeler E, Martens T, Schnell O, Tonn JC, Simon M, Schramm J, Krex D, Schackert G, Reithmeier T, Nikkah G, Sabel M, Steiger HJ, **Schlegel U**, Löffler M, Weller M, Westphal M; for the German Glioma Network. End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. *Neuro Oncol.* 2013;15: 1251 - 1256

Doolittle ND, Korfel A, Lubow MA, Schorb E, **Schlegel U**, Rogowski S, Fu R, Dósa E, Illerhaus G, Kraemer DF, Muldoon LL, Calabrese P, Hedrick N, Tyson RM, Jahnke K, Maron LM, Butler RW, Neuwelt EA. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. *Neurology* 2013;81: 84 - 92

Korfel A, **Schlegel U**. Diagnosis and treatment of primary CNS lymphoma. *Nat Rev Neurol.* 2013;9: 317 - 327

Semmler A, Garbe S, Moskau S, Fisch C, Eter N, **Schlegel U**, Linnebank M. An efficient method for fractionated whole rodent brain radiation. *Neurol Res.* 2013;35: 355 - 359

Korfel A, Elter T, Thiel E, Hänel M, Möhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz CW, Metzner B, Röth A, Birkmann J, **Schlegel U**, Martus P, Illerhaus G, Fischer L. Phase II study of CNS-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. *Haematologica* 2013;98: 364 - 370

Eyding J, Grönheit W, Rother S, Skodda S, Heuser L, Alekseyev A, **Schlegel U**. Optimised rate of specific, revascularising therapies in acute stroke-what is the aim? Considerations from the experience of a tertiary center. *Fortschr Neurol Psychiat.* 2013;81: 69 – 74

Linnebank M, Moskau S, Kowoll A, Semmler A, Bangard C, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Schmidt-Wolf IG, Pels H, **Schlegel U**. Association of transcobalamin c. 776>G with overall survival in patients with primary central nervous system lymphoma. *Br J Cancer.* 2012;107: 1840 - 1843

Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixenberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Pels H, **Schlegel U**, Herrlinger U, Pietsch T, Schramm J, Krex D, Schackert G, Rapp M, Wille C, Blümcke I, Diener HC, Bähr O, Rieger J, Franz K, Seifer V, Plate KH, Wille C, Westphal M, Heidenreich F, Wiese B, Bremer M, Nakamura M, v Deimling A, Klein AC, Pfennig P, Schemmer D, Wick A, Oertel J, Kortmann R, Conrad J, Wiewrodt D, Schmieder K, Wenz F, Bogdahn U, Hau P, Bamberg M, Melms A, Döhner H, Hoppold C, Zaugg K. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. *Lancet Oncol.* 2012;13: 707 - 715

Kuhnenn J, Kowalski T, Steenzen S, Ostermann K, **Schlegel U**. Procarbazine, carmustine and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis. *J Neurooncol.* 2012;109: 433 - 438

Baraniskin A, Kuhnenn J, **Schlegel U**, Schmiegel W, Hahn S, Schroers R. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. *J Neurooncol.* 2012;109: 239 - 244

Skodda S, Grönheit W, **Schlegel U**. Impairment of vowel articulation as a possible marker of disease progression in Parkinson's disease. *PLoS ONE* 2012; 7(2): e32132

Eyding J, Wiebringhaus R, Klein FG, Skodda S, **Schlegel U**, Alekseyez A, Heuser L. Multi-modal CT imaging and recanalizing therapy in acute ischemic stroke – retrospective analysis of a one year single centre experience. *Eur Neurol.* 2012;67: 193 - 199

Szczesni KC, Alekseyev A, **Schlegel U**, Skodda S. [Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids]. *Nervenarzt* 2012;83: 775 - 781

Schmitz-Hübsch T, Eckert O, **Schlegel U**, Klockgether T, Skodda S. Instability of syllable repetition in patients with spinocerebellar ataxia and Parkinson`s disease. *Mov Disord.* 2012; 27: 316 - 319

Baraniskin A, Deckert M, Schulte-Altendorneburg G, **Schlegel U**, Schroers R. Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. *Br J Haematol.* 2012;156: 421 - 432

Baraniskin A, Kuhnenn J, **Schlegel U**, Maghnouj A, Zöllner H, Schmiegel W, Hahn S, Schroers R. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. *Neuro Oncol.* 2012;14: 29 - 33

Flasskamp A, Kotz SA, **Schlegel U**, Skodda S. Acceleration of syllable repetition in Parkinson`s disease is more prominent in the left-side dominant patients. *Parkinsonism Relat Disord.* 2012;18: 343 - 347

Skodda S, Grönheit W, **Schlegel U**. Instability of syllable repetition in progressive supranuclear palsy. *J Neural Transm.* 2012;119: 457 - 462

Steinbeck JA, Stuplich M, Blasius E, Pels H, Glas M, **Schlegel U**, Herrlinger U. Relapse of primary central nervous system lymphoma 13 years after high-dose methotrexate-based polychemotherapy. *J Clin Neurosci.* 2011;18: 1554 - 1555

Deckert M, Engert A, Brück W, Ferreri AJ, Finke J, Illerhaus G, Klapper W, Korfel A, Küppers R, Maarouf M, Montesinos-Rongen M, Paulus W, **Schlegel U**, Lassmann H, Wiestler OD, Siebert R, Deangelis LM. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. *Leukemia.* 2011;25: 1797 - 1807

Patrij K, Reiser M, Wätzel L, Pels H, Kowoll A, Herrlinger U, Engert A, Linnebank M, Schackert G, Vogt-Schaden M, Egerer G, Lamprecht M, Batchelor TT, **Schlegel U**, Schmidt-Wolf IG. International Primary CNS Lymphoma Collaborative Group (IPCG). Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. *Ger Med Sci.* 2011;9: Doc11

Boussier MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoüe A, Fratacci MD; PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM); a randomised , double-blind, parallel-group trial. *Lancet* 2011;377: 2013 - 2022

Skodda S, Visser W, **Schlegel U**. Gender-related patterns of dysprosody in Parkinson disease and correlation between speech variables and motor symptoms. *J Voice.* 2011;25: 76 - 82

Baraniskin A, Kuhnenn J, **Schlegel U**, Chan A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A, Schmiegel W, Hahn SA, Schroers R. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. *Blood.* 2011;117: 3140 - 3146

Hinkerohe D, Wolfkühler D, Haghikia A, Meier C, Faustmann PM, **Schlegel U**. Dexamethasone differentially regulates functional membrane properties in glioma cell lines and primary astrocytes in vitro. *J Neurooncol*. 2011;103: 479 - 489

Skodda S, Flasskamp A, **Schlegel U**. Instability of syllable repetition in Parkinson's disease-influence of levodopa and deep brain stimulation. *Mov Disord*. 2011;26: 728 – 730

Skodda S, Grönheit W, **Schlegel U**. Intonation and speech rate in Parkinson's disease: general and dynamic aspects and responsiveness to levodopa admission. *J Voice*. 2011;25: 199 - 205

Ostermann K, Pels H, Kowoll A, Kuhnhen J, **Schlegel U**. Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. *J Neurooncol*. 2011;103: 635 - 640

Skodda S, Flasskamp A, **Schlegel U**. Instability of syllable repetition as a marker of disease progression in Parkinson's disease: a longitudinal study. *Mov Disord*. 2011;26: 59 - 64

Fischer L, Koch A, **Schlegel U**, Koch HC, Wenzel R, Schröder N, Thiel E, Korfel A. Non-enhancing relapse of a primary CNS lymphoma with multiple diffusion-restricted lesions. *J Neurooncol*. 2011;102: 163 – 166

Skodda S, Visser W, **Schlegel U**. Acoustical analysis of speech in progressive supranuclear palsy. *J Voice*. 2011;25: 725 - 731

Skodda S, Visser W, **Schlegel U**. Vowel articulation in Parkinson's disease. *J Voice*. 2011;25: 467 - 472

Schroers R, Baraniskin A, Heute C, Vorgerd M, Brunn A, Kuhnhen J, Kowoll A, Alekseyev A, Schmiegel W, **Schlegel U**, Deckert M, Pels H. Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. *Eur J Haematol*. 2010;85: 520 - 528

Schroers R, Baraniskin A, Heute C, Kuhnhen J, Alekseyev A, Schmiegel W, **Schlegel U**, Pels HJ. Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. *Eur J Haematol*. 2010;85: 236 -242

Fliessbach K, Rogowski S, Hoppe C, Sabel M, Goeppert M, Helmstaedter C, Calabrese P, Schackert G, Tonn JC, Simon M, **Schlegel U**. Computer-based assessment of cognitive functions in brain tumor patients. *J Neurooncol*. 2010;100: 427 – 437

Stupp R, Hegi M, Neyns B, Goldbrunner R, **Schlegel U**, Clement P, Grabenbauer G, Ochsenbein A, Simon M, Dietrich P, Pietsch T, Hicking C, Tonn J, Diserens A, Pica A, Hermisson M, Krueger S, Picard M, Weller M. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. *J Clin Oncol*. 2010;28: 2712 - 2718

Skodda S, Flasskamp A, **Schlegel U**. Instability of syllable repetition as a model for impaired motor processing: is Parkinson's disease a "rhythm disorder"? *J Neural Transm*. 2010;117: 605 - 612

Hinkerohe D, Smikalla D, Schoebel A, Haghikia A, Zoidl G, Haase CG, **Schlegel U**, Faustmann PM. Dexamethasone prevents LPS-induced microglial activation and astroglial impairment in an experimental bacterial meningitis co-culture model. *Brain Res*. 2010; 1329: 45 - 54

Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf IG, **Schlegel U**. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. *Ann Neurol*. 2010;67: 182 - 189

Grzendowski M, Wolter M, Riemenschneider MJ, Knobbe CB, **Schlegel U**, Meyer HE, Reifenberger G, Stühler K. Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q. *Neuro Oncol*. 2010;12: 243 - 256

Pels H, Juergens A, Schirgens I, Glasmacher A, Schulz H, Engert A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Deckert M, Fimmers R, Urbach H, Schmidt-Wolf IG, **Schlegel U**. Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. *Neuro Oncol*. 2010;12: 720 - 724

Skodda S, Visser W, **Schlegel U**. Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease. *J Neural Transm*. 2010;117:197 - 205

Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, **Schlegel U**, Bergstrom P, Green S, Weir A, Nikolova Z. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. *Br J Cancer*. 2009;101: 1995 - 2004

Herrlinger U, Glantz M, **Schlegel U**, Gisselbrecht C, Cavalli F. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. *Semin Oncol*. 2009;36: 25 - 34

Hoppe C, Fliessbach K, **Schlegel U**, Elger CE, Helmstaedter C. NeuroCog FX: computerized screening of cognitive functions in patients with epilepsy. *Epilepsy Behav*. 2009;16: 298 - 310

Tiemann L, Penner IK, Haupts M, **Schlegel U**, Calabrese P. Cognitive decline in multiple sclerosis: impact of topographic lesion distribution on differential cognitive deficit patterns. *Mult Scler*. 2009;15: 1164 - 1174

Linnebank M, Moskau S, Jürgens A, Simon M, Semmler A, Orlopp K, Glasmacher A, Bangard C, Vogt-Schaden M, Urbach H, Schmidt-Wolf IG, Pels H, **Schlegel U**. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. *Neuro Oncol* 2009;11: 2 - 8

Pels H, Juergens A, Glasmacher A, Schulz H, Engert A, Linnebank M, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Lamprecht M, Hau P, Deckert M, Fimmers R, Bangard C, Schmidt-Wolf IG, **Schlegel U**. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. *J Neurooncol* 2009;91: 299 - 305

Calabrese P, **Schlegel U**. Neurotoxicity of treatment. *Recent Results Cancer Res*. 2009;171: 165 - 174

Schlegel U. Primary CNS lymphoma. *Ther Adv Neurol Disord*. 2009;2: 93 - 104

Skodda S, Rinsche H, **Schlegel U**. Progression of dysprosody in Parkinson's disease over time--a longitudinal study. *Mov Disord* 2009;24: 716 - 722

Haupts MR, Schimrigk SK, Brune N, Chan A, Ahle G, Hellwig K, König FB, **Schlegel U**, Brück W, Gold R. Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology. *J Neurol*. 2008;255: 1272 - 1273

Ahle G, Visser W, Juergens A, **Schlegel U**. Successful treatment of hyperventilation-induced nystagmus in vestibular schwannoma with oxcarbazepine. *J Neurol*. 2008; 255(7): 1093
Skodda S, **Schlegel U**. Speech rate and rhythm in Parkinson's disease. *Mov Disord*. 2008;23: 985 - 992

Kowalski T, Maier C, Reinacher-Schick A, **Schlegel U**. Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options. *Schmerz* 2008;22: 16 - 23

Boes M, Pels H, Klockgether T, Koch A, **Schlegel U**. High-grade B-cell NHL of the brachial plexus followed by infiltration of the spinal cord. *J Neurol*. 2008;255: 135 - 137

Becker A, Vezmar S, Linnebank M, Pels H, Bode U, **Schlegel U**, Jaehde U. Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate. *Int J Clin Pharmacol Ther*. 2007;45: 504 - 515

Linnebank M, Malessa S, Moskau S, Semmler A, Pels H, Klockgether T, **Schlegel U**. Acute methotrexate-induced encephalopathy - causal relation to homozygous allelic state for MTR c.2756A > G (D919G)?. *J Chemother*. 2007;19: 455 - 457

Boes M, Urbach H, Klockgether T, **Schlegel U**. Persistent anarthria following mirror infarction in the anterior choroidal artery territory. *Eur J Neurol*. 2007;14: e6

Courts C, Montesinos-Rongen M, Martin-Subero JI, Brunn A, Siemer D, Zühlke-Jenisch R, Pels H, Jürgens A, **Schlegel U**, Schmidt-Wolf IG, Schaller C, Reifenberger G, Sabel M, Warnecke-Eberz U, Wiestler OD, Küppers R, Siebert R, Deckert M. Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. *J Neuropathol Exp Neurol*. 2007;66: 230 - 237

Linnebank M, Semmler A, Kleijer WJ, van der Sterre ML, Gärtner J, Fliessbach K, Sokolowski P, Köhler W, **Schlegel U**, Klockgether T, Wanders RJ, Schmidt S, Wüllner U, Kemp S. The cystathionine beta-synthase variant c.844_845ins68 protects against CNS demyelination in X-linked adrenoleukodystrophy. *Hum Mutat*. 2006;27: 1063 - 1064

Grommes C, Landreth GE, Sastre M, Beck M, Feinstein DL, Jacobs AH, **Schlegel U**, Heneka MT. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. *Mol Pharmacol*. 2006;70: 1524 - 1533

Fliessbach K, Hoppe C, **Schlegel U**, Elger CE, Helmstaedter C. [NeuroCogFX--a computer-based neuropsychological assessment battery for the follow-up examination of neurological patients]. *Fortschr Neurol Psychiatr*. 2006;74: 643 - 650

Pels H, **Schlegel U**. Primary central nervous system lymphoma. *Curr Treat Options Neurol*. 2006;8: 346 - 357

Schramm J, Blümcke I, Ostertag CB, **Schlegel U**, Simon M, Lutterbach J. Low-grade gliomas - current concepts. *Zentralbl Neurochir* 2006;67: 55 - 66

Schlegel U, Jürgens A, Pels H. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. *Neurology*. 2006;66: 1287

Linnebank M, Kemp S, Wanders RJ, Kleijer WJ, van der Sterre ML, Gärtner J, Fliessbach K, Semmler A, Sokolowski P, Köhler W, **Schlegel U**, Schmidt S, Klockgether T, Wüllner U. Methionine metabolism and phenotypic variability in X-linked adrenoleukodystrophy. *Neurology*. 2006;66: 442 - 443

Palmedo H, Urbach H, Bender H, **Schlegel U**, Schmidt-Wolf IG, Matthies A, Linnebank M, Joe A, Bucerius J, Biersack HJ, Pels H. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. *Eur J Nucl Med Mol Imaging*. 2006;33: 164 - 168

Grommes C, Landreth G, **Schlegel U**, Heneka MT. The non-thiazolidinedione tyrosine-based peroxisome proliferator-activated receptor gamma ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells. *J Pharmacol Exp Ther*. 2005;313: 806 - 813

Fliessbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, Juergens A, Glasmacher A, Schmidt-Wolf IG, Klockgether T, **Schlegel U**. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. *Neurology* 2005;64: 1184 - 1188

Linnebank M, Pels H, Kleczar N, Farmand S, Fliessbach K, Urbach H, Orlopp K, Klockgether T, Schmidt-Wolf IG, **Schlegel U**. MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. *Neurology* 2005;64: 912 - 913

Herrlinger U, Korfel A, Hebart H, **Schlegel U**, Plasswilm L, Illerhaus G, Finke J, Krüger W, Montemurro M, Wolf T, Thiel E, Bamberg M, Weller M, Kanz L. Centers for Neuro-Oncology and Lymphoma, University of Tübingen, Germany. Meeting report: primary central nervous system lymphoma: standards of care and future perspectives. *Onkologie*. 2005;28: 109 -111

Orlopp K, Schmidt-Wolf IG, Urbach H, **Schlegel U**. [Acute central nervous symptoms in oncologic patients.] *Internist (Berl)* 2005;46: 19 - 29

Pels H, Montesinos-Rongen M, Schaller C, **Schlegel U**, Schmidt-Wolf IG, Wiestler OD, Deckert M. VH gene analysis of primary CNS lymphomas. *J Neurol Sci*. 2005;228: 143 - 147

Pels H, Montesinos-Rongen M, Schaller C, Van Roost D, **Schlegel U**, Wiestler OD, Deckert M. Clonal evolution as pathogenetic mechanism in relapse of primary CNS lymphoma. *Neurology* 2004;63: 167 - 169

Felsberg J, Erkwow A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, **Schlegel U**, Schramm J, Wiestler OD, Reifenberger G. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. *Brain Pathol*. 2004;14: 121 - 130

Linnebank M, Schmidt S, Kölsch H, Linnebank A, Heun R, Schmidt-Wolf IG, Glasmacher A, Fliessbach K, Klockgether T, **Schlegel U**, Pels H. The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. *Br J Cancer*. 2004;90: 1969 - 1971

Schmidt S, Schneider T, Schmidt-Wolf IG, Ko Y, **Schlegel U**, Klockgether T, Hertfelder HJ. C1-inhibitor activity and plasma concentrations in patients with monoclonal gammopathies: implications for treatment with recombinant interferon-beta 1b. *Mult Scler*. 2004;10: 243 -244

Harzheim M, **Schlegel U**, Urbach H, Klockgether T, Schmidt S. Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients. *J Neurol Sci*. 2004;217: 217 - 223

Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz A, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, **Schlegel U**. Primary central nervous system lymphoma: results of a pilot/phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. *J Clin Oncol*. 2003;21: 4489 - 4495

Paus S, Urbach H, Klockgether T, **Schlegel U**. Meningioma of the optic nerve sheath: treatment with hydroxyurea. *J Neurol Neurosurg Psychiatry* 2003;74: 1348 - 1350

Fliessbach K, Urbach H, Helmstaedter C, Pels H, Glasmacher A, Kraus JA, Klockgether T, Schmidt-Wolf IG, **Schlegel U**. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. *Arch Neurol*. 2003;60: 563 - 568

Pels H, Schulz H, **Schlegel U**, Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. *Onkologie* 2003;26: 351 - 354

Schmidt-Wolf IG, Rockstroh JK, **Schlegel U**, Pels H, Mey U, Strehl J, Weiss R, Huhn D. Treatment options of AIDS-related lymphoma. *Expert Opin Pharmacother*. 2003;4: 1331 - 1343

Kristof RA, Neuloh G, Hans V, Urbach H, **Schlegel U**, Simon M, Deckert M, Schramm J. Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III. *J Neurooncol*. 2002;59: 231 -237

Zander T, Kraus JA, Grommes C, **Schlegel U**, Feinstein D, Klockgether T, Landreth G, Konigsknecht J, Heneka MT. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. *J Neurochem*. 2002;81: 1052 - 1060

Zander T, Nettekoven W, Kraus JA, Pels H, Ko YD, Vetter H, Klockgether T, **Schlegel U**. Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma. *J Neurol*. 2002;249: 1055 - 1057

Ziske CG, Schöttker B, Gorschlüter M, Mey U, Kleinschmidt R, **Schlegel U**, Sauerbruch T, Schmidt-Wolf IG. Acute transient encephalopathy after paclitaxel infusion: report of three cases. *Ann Oncol*. 2002;13: 629 – 631

Kraus JA, Oster C, Sörensen N, Berthold F, **Schlegel U**, Tonn JC, Wiestler OD, Pietsch T. Human medulloblastomas lack point mutations and homozygous deletions of the hSNF5/INI1 tumour suppressor gene. *Neuropathol Appl Neurobiol*. 2002;28: 136 - 141

Schmidt-Wolf IG, Rockstroh JK, **Schlegel U**, Pels H, Weiss R, Huhn D. New aspects in the treatment of AIDS-related lymphoma. *Eur J Med Res*. 2002;7: 295 – 303

Kraus JA, Wenghoefer M, Glesmann N, Mohr S, Beck M, Schmidt MC, Schröder R, Berweiler U, Roggendorf W, Dietsch S, Dietzmann K, Heuser K, Müller B, Fimmers R, von Deimling A, **Schlegel U**. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. *J Neurooncol*. 2001;52: 263 – 272

Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, Schmidt-Wolf IG, Helmstaedter C, Fliessbach K, Deckert M, Van Roost D, Fimmers R, Bode U, Klockgether T. Combined systemic and intraventricular chemotherapy in primary CNS Lymphoma : a pilot study. *J Neurol Neurosurg Psychiatry* 2001;71: 118 – 122

Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, Krex D, Klockgether T, Reiffenberger G, **Schlegel U**. Molecular genetic alterations in glioblastomas with oligodendroglial component. *Acta Neuropathol.* 2001;101: 311 - 320

Schmidt S, Träber F, Block W, Keller E, Pohl C, von Oertzen J, Schild H, **Schlegel U**, Klockgether T. Phenotype assignment in symptomatic female carriers of X-linked adrenoleukodystrophy. *J Neurol.* 2001;248: 36 - 44

Schlegel, U. The DNA-repair gene MGMt and the clinical response of gliomas to alkylating agents. *Engl J Med.* 2001;344: 686 - 687

Jung G, Eisner W, Brandl M, Fraunberger P, Reiffenberger G, **Schlegel U**, Wiestler OD, Reulen HJ, Wilmanns W. Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for *in situ* t-cell activation and therapeutic activity. *Int J Cancer* 2001;91: 225 – 230

Pels H, Vogt I, Klockgether T, **Schlegel U**. Primary non-Hodgkin's lymphoma of the spinal cord. *Spine* 2000;25: 2262 – 2264

Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G, **Schlegel U**. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. *J Neurooncol* 2000;48: 89 - 94

Kraus JA, Wenghoefer M, Schmidt MC, von Deimling A, Berweiler U, Roggendorf W, Dietsch S, Dietzmann K, Müller B, Heuser K, Reiffenberger G, **Schlegel U**. Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. *J Neurol.* 2000;247: 455 – 460

Lütjohann D, Papassotiropoulos A, Björkhem I, Locatelli S, Bagli M, Oehring RD, **Schlegel U**, Jessen F, Rao ML, von Bergmann K, Heun R. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. *J Lipid Res.* 2000;41: 195 - 198

Pels H, Deckert-Schlüter M, Glasmacher A, Kleinschmidt R, Oehring RD, Fischer HP, Bode U, **Schlegel U**. Primary central nervous system lymphoma: A clinicopathological study of 28 cases. *Hematol Oncol.* 2000;18: 21 - 32

Schlegel U, Schmidt-Wolf IG, Deckert M. Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. *J Neurol Sci.* 2000;181: 1 – 12

Oehring RD, Miletic M, Valter MM, Pietsch T, Neumann J, Fimmers R, **Schlegel U**. Vascular endothelial growth factor (VEGF) in astrocytic gliomas – a prognostic factor ? *J. Neurooncol.* 1999;45: 117 – 125

Riemenschneider MJ, Büschges R, Wolter M, Reiffenberger J, Boström J, Kraus JA, **Schlegel U**, Reiffenberger G. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. *Cancer Res.* 1999;59: 6091 – 6096

Schröder R, Keller E, Flacke S, Schmidt S, Pohl C, Klockgether T, **Schlegel U**. MRI findings in Hirayama's disease: flexion induced cervical myelopathy or intrinsic motor neuron disease. *J Neurol.* 1999;246: 1069 – 1074

Schmidt S, Hertfelder HJ, von Spiegel T, Hering R, Harzheim M, Lassmann H, Deckert-Schlüter M, **Schlegel U**. Lethal capillary leak syndrome after a single administration of interferon beta-1b. *Neurology* 1999;53: 220 – 222

Schlegel U, Pels H, Oehring R, Blümcke I. Neurologic sequelae of treatment of primary CNS lymphomas. *J Neurooncol.* 1999;43: 277 – 286

Schröder R, Mundegar RR, Treusch M, **Schlegel U**, Blümcke I, Owaribe K, Magin TM. Altered distribution of plectin / HD1 in dystrophinopathies. *Eur J Cell Biol.* 1997;74: 165 – 171

Waha A, Baumann A, Wolf HK, Fimmers R, Neumann J, Kindermann D, Astrahantseff K, Blümcke I, von Deimling A, **Schlegel U**. Lack of prognostic relevance of alterations in the epidermal growth factor receptor - transforming growth factor-alpha pathway in human astrocytic gliomas. *J Neurosurg.* 1996;85: 634 - 641

Kraus JA, Bolln C, Wolf HK, Neumann J, Kindermann D, Fimmers R, Forster F, Baumann A, **Schlegel U**. Tp53 alterations and clinical outcome in low grade astrocytomas. *Genes Chromosomes Cancer* 1994;10: 143 – 149

Schlegel U. p53: an important or most overvalued tumor gene? [p53: Wichtigstes oder am meisten überschätztes Tumorgen]? *Laryngorhinootologie* 1994;73: 651 – 653

Schlegel U. Mechanism of molecular development of human glioma. [Molekulare Entstehungsmechanismen menschlicher Gliome]. *Nervenarzt* 1993;64: 485 – 493

Schlegel U, Rosenfeld MR, Volkenandt M, Rosenblum M, Dalmau J, Furneaux HM. p53 gene mutations in primary lung tumors are conserved in their brain metastases. *J Neurooncol.* 1992;14: 93 – 100

Ebel H, **Schlegel U**, Klosterkötter J. Chronic schizophreniform psychosis in primary hyperparathyroidism. [Chronische schizophrenieähnliche Psychose bei primärem Hyperparathyreoidismus]. *Nervenarzt* 1992;63: 180 – 183

Volkenandt M, **Schlegel U**, Nanus DM, Albino AP. Mutational analysis of the human p53 gene in malignant melanoma. *Pigment Cell Res.* 1991;4: 35 – 40

Schlegel U, Moots PL, Rosenblum MK, Thaler HT, Furneaux HM. Expression of transforming growth factor alpha in human gliomas. *Oncogene* 1990;5: 1839 – 1842

Kenny MK, **Schlegel U**, Furneaux H, Hurwitz J. The role of human single-stranded DNA binding protein and its individual subunits in simian virus 40 DNA replication. *J Biol Chem.* 1990;265: 7693 – 7700

Schlegel U, Clarenbach P, Cordt A, Steudel A. Cerebral sarcoidosis presenting as supranuclear gaze palsy and hypokinetic rigid syndrome. *Mov Disord.* 1989;4: 274 - 277

Schlegel U, Jerusalem F, Tackmann W, Cordt A, Tsuda Y. Benign juvenile focal muscular atrophy of upper extremities - a familial case. *J Neurol Sci.* 1987;80: 351 – 353

Schlegel U. Neurosarcoidosis: diagnosis and therapy. [Neurosarkoidose: Diagnostik und Therapie]. *Fortschr Neurol Psychiatr.* 1987;55: 1 – 15

Schlegel U, Tackmann W, Cordt A. Optic neuritis caused by herpes zoster ophthalmicus. Case report and review of the literature. [Neuritis nervi optici bei Herpes zoster ophthalmicus]. *Nervenarzt* 1986;57: 298 – 301

Ayami M.S., Grzella S., Kykalos S., Viebahn R., Schenker P.

Pancreas Donor Risk Index but Not Pre-Procurement Pancreas Allocation Suitability Score Predicts Pancreas Graft Survival: A Cohort Study from a Large German Pancreas Transplantation Center.

Annals of Transplantation 23, 434-441 (2018).

Dralle H., Kols K., Witzigmann H., Viebahn R.

The Primary Treatment of Anal Cancer.

Der Chirurg 89, 152-154 (2018).

Suwelack B., Sommerer C., Dragun D., Witzke O., Hugo C., Kamar N., Merville P., Hauser A., Schenker P., Junge M., Nashan B., Thaiss F.

The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients.

American Journal of Transplantation 18 (Suppl. 4), 259-260 (2018).

Proneth A., Schnitzbauer A.A., Schenker P., Wunsch A., Rauchfuss F., Arbogast H., Manekeller S., Nadalin S., Heise M., Ströhlein M.A., Banas B., Schemmer P., Becker T., Bechstein W.O., Pascher A., Viebahn R., Geissler E.K., Schlitt H.J., Farkas S.A.

Extended Pancreas Donor Program - The EXPAND Study A Prospective Multicenter Trial Testing the Use of Pancreas Donors Over Age 50.

Transplantation (2018, Feb. 5) Epub ahead of print

Kamar N., Merville P., Sommerer C., Suwelack B., Dragun D., Hauser I.A., Schenker P., Witzke O., Hugo C., Junge M., Nashan B., Thaiss F.

12 Months Data on Infections From Athena Study Show Significantly Less CMV-and BKV-Events with Everolimus-Based Versus Tacrolimus-MPA Regimen in De Novo Renal Transplant Recipients.

Transplant International 31 (1), 14 (2018).

Merville P., Kamar N., Dragun D., Sommerer C., Suwelack B., Schenker P., Hauser I.A., Witzke O., Hugo C., Junge M., Thaiss F., Nashan B.

12 Months Outcomes on Allograft Function with Everolimus-CNI vs Tacrolimus-MPA Regimen in De Novo Renal Transplant Recipients: The Athena Study.

Transplant International 31 (1), 15 (2018).

Kamar N., Merville P., Suwelack B., Sommerer C., Dragun D., Hauser I.A., Schenker P., Witzke O., Hugo C., Junge M., Thaiss F., Nashan B.

12 Months Safety and Efficacy Data from Athena Study on Everolimus-Based vs Tacrolimus-MPA Regimen in De Novo Kidney Transplant Recipients.

Transplant International 31 (1), 2 (2018).

Thaiss F., Sommerer C., Suwelack B., Dragun D., Schenker P., Hauser I.A., Witzke O., Hugo C., Kamar N., Merville P.G., Junge M., Nashan B.

12 Months Data from Athena Study Show Comparable Safety and Efficacy of Modern Everolimus-Based Regimen vs. Conservative Tacrolimus-MPA-Based Regimen in De Novo Renal Transplant Recipients.

Transplant International 30 (4), 20 (2017).

Bialobrzecka M., Berger L., Wunsch A., Schenker P., Klein T., Viebahn R.

A rare complication after retroperitoneoscopic donor nephrectomy.

Transplant International 30 (4), 44 (2017).

Pagonas N., Seidel M., Bauer F., Seibert FS., Rohn B., Klein T., Wunsch A., Babel N., Viebahn R., Westhoff T.H.

Association of serum acid lowering therapy and resistance index after renal transplantation.

Transplant International 30 (4), 32 (2017).

Dragun D., Sommerer C., Suwelack B., Schenker P., Hauser I., Witzke O., Hugo C., Kamar N., Merville P., Junge M., Thaiss F., Nashan B.

ATHENA study outcomes on allograft function after 12 months with Everolimus-CNI vs Tacrolimus-MPA regimen in de novo renal transplant recipients.

Transplant International 30 (2), 562 (2017).

Sommerer C., Suwelack B., Dragun D., Schenker P., Hauser I.A., Witzke O., Hugo C., Kamar N., Merville PG., Junge M., Nashan B., Thaiss F.

ATHENA study: outcomes on allograft function after 12 months of modern Everolimus-based vs. conservative Tacrolimus-MPA regimen in de novo renal transplant recipients.

Transplant International 30 (4), 20 (2017).

Schnuelle P., Schmitt W.H., Weiss C., Habicht A., Renders L., Zeier M., Drüschler F., Heller K., Pisarski P., Banas B., Krämer B.K., Jung M., Lopau K., Olbricht C.J., Weihprecht H., Schenker P., De Fijter J.W., Yard B.A., Benck U.

Effects of dopamine donor pretreatment on graft survival after kidney transplantation: a randomized trial.

Clinical Journal of the American Society of Nephrology 12 (3), 493-501 (2017).

Sommerer C., Suwelack B., Dragun D., Hauser I., Schenker P., Witzke O., Hugo C., Kamar N., Merville P., Junge M., Nashan B., Thaiss F.

Everolimus-based vs. Tacrolimus-MPA regimen in de novo kidney transplant recipients: 12 months safety and efficacy data from ATHENA study.

Transplant International 30 (2), 160 (2017).

Berger L., Bialobrzecka M., Schenker P., Wunsch A., Viebahn R.
Influence of complications on the outcome after pancreas transplantation.
Transplant International 30 (4), 10 (2017).

Thieme C., Weist B., Muskes A., Reinke P., Viebahn R., Westhoff TH., Babel N.
Monitoring of donor-reactive t cells using donor spleen cells and/or IFNg-based assays
might underestimate donor-reactive t cell immunity.
Transplant International 30 (4), 20 (2017).

Arns W., Huppertz A., Rath T., Ziefle S., Rump LC., Hansen A., Budde K., Lehner LJ.,
Shipkova M., Baeumer D., Kroeger I., Sieder C., Klein T., Schenker P.
Pharmacokinetics and clinical outcomes of generic Tacrolimus (hexal) versus branded
Tacrolimus in de novo kidney transplant patients: a multicenter, randomized trial.
Transplantation 101 (11), 2780-2788 (2017).

Suwelack B., Dragun D., Sommerer C., Schenker P., Hauser I.A., Witzke O., Hugo C.,
Kamar N., Merville P.G., Junge M., Nashan B., Thaïss F.
Reduced incidence of CMV-events with modern Everolimus-based vs conservative
Tacrolimus-MPA-based regimen in de novo renal transplant recipients: 12 months data
on infections from ATHENA study.
Transplant International 30 (4), 15 (2017).

Bauer J., Grzella S., Viebahn R., Schenker P.
Results after renal transplantation from deceased donors with acute kidney injury.
Transplant International 30 (4), 21 (2017).

Bauer F., Pagonas N., Seibert F.S., Zidek W., Viebahn R., Babel N., Westhoff T.H.
Serum uric acid and arterial function after renal transplantation.
Annals of Transplantation 22, 431-439 (2017).

Nashan B., Sommerer C., Suwelack B., Dragun D., Hauser I., Schenker P., Witzke O.,
Hugo C., Kamar N., Merville P., Junge M., Thaïss F.
Significantly less CMV- and BKV-events with Everolimus-based vs. Tacrolimus-MPA
regimen in de novo renal transplant recipients: 12 months data on infections from
athena study.
Transplant International 30 (2), 162 (2017).

Stervbo U., Klein T., Nienen M., Viebahn R., Westhoff T.H., Babel N.
TCR NGS based evidence for differential diagnosis and personalized therapy in BKV
nephropathy.
Transplant International 30 (2), 357-358 (2017).

Stervbo U., Klein T., Nienen M., Viebahn R., Westhoff T.H., Babel N.

TCR NGS based evidence for differential diagnosis and personalized therapy in BKV nephropathy.

Transplant International 30 (4), 30 (2017).

Michita RT., Chies J.A.B., Heinemann FM., Wunsch A., Schenker P., Viebahn R., Rebmann V., Horn P.A.

The contribution of MICA-129 Val/ Met polymorphism on graft rejection and CMV infection in simultaneous pancreas and kidney transplant patients - one-year follow-up.

Transfusion Medicine and Hemotherapy 44 (1), 73 (2017).

Michita R.T., Chies J.A., Heinemann F.M., Horn P.A., Wunsch A., Schenker P., Viebahn R., Rebmann V.

The contribution of MICA-129 Val/Met polymorphism on graft rejection and CMV infection in simultaneous pancreas and kidney transplant patients - one-year follow-up.

HLA 89 (6), 402 (2017).

Al-Batran S.E., Goetze T.O., Mueller D.W., Vogel A., Winkler M., Lorenzen S., Novotny A., Pauligk C., Homann N., Jungbluth T., Reissfelder C., Caca K., Retter S., Horndasch E., Gump J., Bolling C., Fuchs K.H., Blau W., Padberg W., Pohl M., Wunsch A., Mic

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III tri

BMC Cancer 17 (1), 893 (2017).

Ziemann M., Heßler N., König I.R., Lachmann N., Dick A., Ditt V., Budde K., Reinke P., Eisenberger U., Suwelack B., Klein T., Westhoff T.H., Arns W., Ivens K., Habicht A., Renders L., Stippel D., Bös D., Sommer F., Görg S., Nitschke M., Feldkamp T., Heine

Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation.

Nephrology Dialysis Transplantation 32 (5), 880-889 (2017).

Stervbo U., Nienen M., Weist B., Kuchenbecker L., Wehler P., Viebahn R., Westhoff T.H., Reinke P., Volk HD., Babel N.

Viremia clearance rate correlates with exhaustion state but not receptor repertoire shape of BKV-specific t-cells in renal transplant patients with severe BKV infection.

Transplant International 30 (4), 25 (2017).

Viebahn R.

Tumorerkrankungen vor und nach Organtransplantation. Dringlichkeit und erfolgsaussicht beim onkologisch vorerkrankten Patienten.

Current congress (Karl Demeter Verlag im Georg Thieme Verlag KG), 13 (2017).

Schenker P.

Scoring Systeme bei der Pankreasallokation. P-PASS und PDRI im Vergleich.

Current congress (Karl Demeter Verlag im Georg Thieme Verlag KG), 10 (2017).

Kykalos S., Wunsch A., Klein T., Viebahn R., Schenker P.

Successful Simultaneous Pancreas-Kidney Re-transplantation in a Highly Human Leukocyte Antigen-Sensitized Patient.

Transplantation Proceedings 49 (7), 1652-1655 (2017).

Bauer F., Pagonas N., Seibert F.S., Zidek W., Viebahn R., Babel N., Westhoff T.H.

Serum Uric Acid and Arterial Function After Renal Transplantation.

Annals of Transplantation 22, 431-439 (2017).

Wahba R., Suwelack B., Arns W., Cakiroglu F., Eisenberger U., Feldkamp T., Hansen A., Ivens K., Klein T., Kribben A., Kurschat C., Lange U., Mühlfeld A., Nitschke M., Reuter S., Schulte K., Viebahn R., Woitas R., Hellmich M., Stippel DL.

Rescue allocation and recipient oriented extended allocation in kidney transplantation-influence of the EUROTRANSPLANT allocation system on recipient selection and graft survival for initially nonaccepted organs.

Transplant International doi: 10.1111/tri.12993 [Epub ahead of print] (2017).

Schmiegel W., Scott R.J., Dooley S., Lewis W., Meldrum C.J., Pockney P., Draganic B., Smith S., Hewitt C., Philimore H., Lucas A., Shi E., Namdarian K., Chan T., Acosta D., Ping-Chang S., Tannapfel A., Reinacher-Schick A., Uhl W., Teschendorf C., Wolters

Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.

Molecular Oncology 11 (2), 208-219 (2017).

Arns W., Huppertz A., Rath T., Ziefler S., Rump L., Hansen A., Baeumer D., Budde K., Lehner L., Klein T., Schenker P.

Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal (R) with Prograf (R) Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.

American Journal of Transplantation 16 (3), 456-457 (2016).

Assfalg V., Hüser N, van Meel M., Haller B., Rahmel A., de Boer J., Matevossian E., Novotny A., Knops N., Weekers L., Friess H., Pratschke J., Függer R., Janko O., Rasoul-Rockenschaub S., Bosmans J.L., Broeders N., Peeters P., Mourad M., Kuypers D., Slavi

High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: Success or waste of organs? The Eurotransplant 15-year all-centre survey.

Nephrology, Dialysis, Transplantation 31 (9), 1515-1522 (2016).

Ayami M.S., Klein T., Kykalos S., Viebahn R., Schenker P.

PDR1 and P-PASS in pancreas transplantation which is scoring more?

Transplant International 29 (3), 12-13 (2016).

Berger L., Bialobrzecka M., Schenker P., Wunsch A., Viebahn R.

Influence of positive duodenal swabs on the outcome and progress after pancreas transplantation - actual germ spectrum

Transplant International 29 (3), 33 (2016).

Bialobrzecka M., Berger L., Viebahn R., Wunsch A., Schenker P.

Contrast enhanced ultrasound of the pancreas graft

Transplant International 29 (3), 33 (2016).

Bialobrzecka M., Viebahn R., Wunsch A., Berger L.

Stenting of the pancreatic duct as a therapeutic option in the treatment of pancreatic fistula after pancreas transplantation

Transplant International 29 (3), 41 (2016).

Bolesta K., Kühn P., Wunsch A., Viebahn R.

Long term quality of life after combined pancreas-kidney transplantation

Transplant International 29 (3), 22 (2016).

Grzella S., Tischert A., Wunsch A., Viebahn R., Schenker P.

Unexpected reason for pancreas-graft dysfunction: giant arteriovenous fistula

Transplant International 29 (3), 42 (2016).

Pagonas N., Seibert F., Bauer F., Seidel M., Zidek W., Kykalos S., Klein T., Viebahn R., Westhoff T.

The impact of blood pressure variability on graft survival and mortality after kidney transplantation

Transplant International 29 (3), 28 (2016).

Proneth A., Schnitzbauer A., Viebahn R., Schenker P., Arbogast H., Manekeller S., Nadalin S., Heise M., Strohle M., Banas B., Schemmer P., Becker T., Bechstein W., Pascher A., Rauchfuss F., Geissler E., Schlitt H.J., Farkas S.

Extended pancreas donor program - the EXPAND study: A prospective multicenter trial testing the use of pancreas donors over age 50

Transplant International 29 (3), 50 (2016).

Rath T., Ziefle S., Hansen A., Rump L.C., Budde K., Lehner L., Klein T., Schenker P., Kroeger I., Huppertz A., Arns W.

Results from SparTacus - a multicentre, prospective randomized study: evaluation of pk profile and clinical outcomes with tacrolimus hexal (r) versus prograf (r) in de novo renal transplant recipients

Transplant International 29 (3), 36 (2016).

Viebahn R.

Der Transplantationsskandal war heilsam.

Westfälisches Ärzteblatt (6), 17 (2016).

Schenker P.

The elderly pancreas transplant recipient.

Transplant International 29 (7), 807-809 (2016).

Shah S., Usta S., Stricker I., Stern J., Tannapfel A., Viebahn R.

Is an improvement of lymphadenectomy through an intraoperative representation of sentinel lymph nodes in rectum carcinoma patients under use of indocyanine green possible?- A prospective study

The Internist 57 (1), S7-S8 (2016).

Sommerer C., Suwelack B., Dragun D., Schenker P., Hauser I.A., Nashan B., Thaiss F.

Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patient

Trials 17, 92 (2016).

Ueberberg S., Tannapfel A., Schenker P., Viebahn R., Uhl W., Schneider S., Meier J.J.
Differential expression of cell-cycle regulators in human beta-cells derived from
insulinoma tissue.
Metabolism 65 (5), 736-746 (2016).

Wunsch A., Bialobrzecka M., Berger L., Schenker P., Tischert A., Viebahn R.
Role of endovascular procedures in the management of arterial complications following
pancreas transplantation
Transplant International 29 (3), 13 (2016).

Arns W., Rath T., Rump L.C., Baeumer D., Budde K., Schenker P.

Spartacus: a multicentre, prospective randomised study comparing tacrolimus hexal (r) versus prograf (r) based regimen in de novo renal transplant recipients.

Transplant International 28 (S2), 26 (2015).

Beer M.V., Hahn K., Diederichs S., Fabry M., Singh S., Spencer S.J., Salber J., Möller M., Shard A.G., Groll J.

Quantifying ligand-cell interactions and determination of the surface concentrations of ligands on hydrogel films: The measurement challenge.

Biointerphases 10 (2), 021007 (2015).

Benck U., Schnuelle P., Habicht A., Renders L., Zeier M., Heller K., Pisarski P., Banas B., Kramer B.K., Jung M., Lopau K., Olbricht C.J., Weihprecht H., Schenker P., De Fijter H.W., Yard B., Schmitt W.H.

Effects of dopamine donor pretreatment on graft function after kidney transplantation: five-year follow-up of a randomized controlled trial.

Transplant International 28 (S2), 3 (2015).

Bialobrzecka M., Kühn P., Berger L., Wunsch A., Viebahn R.

Contrast-enhanced ultrasonography of the pancreas graft.

Transplant International 28 (S2), 18 (2015).

Carolus A. E., Schenker P., Dombert T., Fontana J., Viebahn R., Schmieder K., Brenke C.

Sonographic examination of the median nerve in dialysis patients and after renal transplantation.

Brain and Behavior 5 (12) e00406 (2015).

Dragun D., Sommerer C., Suwelack B., Hauser I.A., Schenker P., Baumer D., Nashan B., Thaiss F.

Design and rationale of athena study: a 12-month study evaluating everolimus versus standard regimen in de novo renal transplant recipients-baseline data.

Transplant International 28 (S2), 24 (2015).

Roedel C., Graeven U., Fietkau R., et al. (German Rectal Cancer Study Group).

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.

Lancet Oncology 16 (8), 979-989 (2015).

Schenker P., Arns W., Rath T., Rump L.C., Baeumer D., Budde K.

Evaluation of pharmacokinetic and clinical outcomes with Tacrolimus hexal (r) versus Prograf (r) based regimen in de novo renal transplant patients: results from a randomised, multicentre study (SparTacus)

Transplant International 28 (4), 820 (2015).

Schenker P., Klein T., Grzella S., Kykalos S., Viebahn R.

Once-daily modified-release tacrolimus in de novo simultaneous pancreas-kidney transplant patients: a five-year prospective study.

Transplant International 28 (S2), 30 (2015).

Sommerer C., Suwelack B., Dragun D., Hauser I., Schenker P., Baumer D., Nashan B., Thaiss F.

12-Month Athena Study: Everolimus vs. Standard Regimen in De Novo Renal Transplant Recipients

American Journal of Transplantation 15 (3), (2015).

Sommerer C, Suwelack B, Dragun D, Hauser I, Schenker P, Baumer D, Nashan B, Thaiss F

12-Month Athena Study: Everolimus vs. Standard Regimen in De Novo Renal Transplant Recipients

Transplant International 28 (4), 450 (2015).

Wunsch A., Bialobrzecka M., Jazra M., Kühn P., Schenker P., Viebahn R.

Is it possible to predict renal transplant function by an estimation of the gfr using the available donor data?

Transplant International 28 (S2), 56 (2015).

Berger L., Bialobrzecka M., Schenker P., Viebahn R., Wunsch A.

Patient and graft survival after pancreas retransplantation: a retrospective analysis of the outcome in a single center.

Transplant International 27 (S3), 31 (2014).

Bialobrzecka M., Wunsch A., Berger L., Kühn P., Viebahn R.

Different ways of protecting a kidney transplant during aortic or aortoiliac reconstruction.

Transplant International 27 (S3), 29 (2014).

Grzella S., Viebahn R., Schenker P.

Comparison of histidine-tryptophan-ketoglutarate (HTK) solution and University of Wisconsin (UW) solution in pancreas transplantation.

Transplant International 27 (S3), 18 (2014).

Jazra M., Kuhn P., Schenker P., Wunsch A., Kykalos S., Viebahn R.

Two cases of enterohemorrhagic escherichia coli (EHEC) detection in solid-organ transplant recipients.

Transplant International 27 (S3), 29 (2014).

Kühn P., Bolesta K., Rifaie N., Schenker P., Wunsch A., Viebahn R.

Long term quality of life after combined pancreas-kidney transplantation.

Transplant International 27 (S3), 35 (2014).

Kykalos S., Jazra M., Kuhn P., Wunsch A., Viebahn R.

Results of living donor kidney transplantations from donors aged more than 65 years.

Transplant International 27 (3), 36 (2014).

Nardi F.D., Kuehn P., Wunsch A., Bicalho M.D., Heinemann F.M., Horn P.A., Viebahn R., Rebmann V.

HLA-E polymorphisms impacts on human cytomegalovirus reinfection in simultaneous kidney-pancreas transplantation.

Tissue Antigens 84 (1), 72-73 (2014).

Pillokeit N., Jazra M., Schenker P., Wunsch A., Viebahn R.

Relevance of ureteral complications in kidney transplant patients.

Transplant International 27 (S3), 29 (2014).

Schenker P., Klein T., Jazra M., Kuhn P., Grzella S., Viebahn R.
Renal transplantation using donors older than 80 years: a single-center experience.
Transplant International 27 (S3), 30 (2014).

Teodoridis A., Schenker P., Wunsch A., Viebahn R.
Long-term mortality in patients after simultaneous pancreas-kidney-transplantation.
Transplant International 27 (S3), 38 (2014).

Touloumtzidis A., Sostmann B., Hilgers N., Renter M.A., Kühn P., Goretzki P.E.,
Lammers B.J.
Functional long-term results after rectal cancer surgery--technique of the athermal
mesorectal excision.
International Journal of Colorectal Disease 29 (3), 285-92 (2014).

Viebahn R.
Gesundheitsforschung – Versorgungsforschung zur Verbesserung der Qualität [Health
care research for improving quality].
Zentralblatt für Chirurgie 139 (2), 139-42 (2014).

Viebahn R., Kuhn P., Wunsch A., Schenker P.
Delisting and "inactive status": survey on ethical aspects of managing a waiting list in
times of decreasing organ donation.
Transplant International 27 (S3), 17 (2014).

Walter M., Jazra M., Kykalos S., Kuehn P., Michalski S., Klein T., Wunsch A., Viebahn
R., Schenker P.
125 cases of duodenoduodenostomy in pancreas transplantation: a single-centre
experience of an alternative enteric drainage.
Transplant International 27 (8), 805-15 (2014).

Witzke O., Opgenoorth M., Sommerer C., Suwelack B., Lehner F., Dragun D., Hauser
I.A., Schenker P., Baumer D., Nashan B., Thaiss F.
12-month ATHENA study: everolimus vs. standard regimen in de novo renal transplant
recipients.
Transplant International 27 (S3), 51 (2014).

Floros G., Moder A., Kykalos S., Jazra M., Wunsch A., Viebahn R.
Pneumonia in kidney and kidney-pancreas transplant patients.
Transplant International 26 (S1), 42 (2013).

Goetting S., Kuehn P., Schenker P., Wunsch A., Klein T., Muermann K., Viebahn R.
Are marginal donor criteria a risk factor for graft thrombosis in pancreas-transplantation?
Transplant International 26 (S1), 38 (2013).

Jazra M., Klein T., Schenker P., Wunsch A., Kykalos S., Viebahn R.
Severe anemia due to parvo virus b19 infection in a patient after living donor kidney
transplantation - successful treatment using high-dose immunoglobulins.
Transplant International 26 (S1), 44 (2013).

Kadmon M., Ganschow P., Gillen S., Hofmann H.S., Braune N., Johannink J., Kühn P.,
Buhr H.J., Berberat P.O.
The competent surgeon. Bridging the gap between undergraduate final year and
postgraduate surgery training].
Der Chirurg 84 (10), 859-868 (2013).

Kuehn P., da Silva Nardi F., Wunsch A., Heinemann F.M., Horn P.A., Viebahn R.,
Rebmann V.
MICB - a ligand for the activating natural killer receptor NKG2D-is a marker for the
prediction of graft rejection after combined kidney-pancreas transplantation.
Transplant International 26 (S1), 14 (2013).

Kuehn P., Goetting S., Muermann K., Schenker P., Wunsch A., Viebahn R.
Single center study: outcome after 428 combined pancreas-kidney-transplantations.
Transplant International 26 (S1), 14 (2013).

Kuehn P., Goetting S., Schenker P., Wunsch A., Viebahn R.
Development of donor criteria of combined pancreas-kidney-donation within the last
10 years.
Transplant International 26 (S1), 37 (2013).

Kykalos S., Wunsch A., Klein T., Mitchell A., Viebahn R.
Successful pancreas/kidney re-transplantation by a patient with very high panel
reactive antibodies. our desensitization protocol.
Transplant International 26 (S1), 31 (2013).

Moder A., Wunsch A., Viebahn R.

Autotransplantation for the treatment of severe renal artery stenosis and aneurysm in a solitary kidney after repeated coiling: a case report.

Transplant International 26 (S1), 47 (2013).

Porwol D., Wunsch A., Kuehn P., Schenker P., Viebahn R.

Demographic challenges of simultaneous pancreas-kidney transplantation (spkt) 2005 to 2012: a single-center experience.

Transplant International 26 (S1), 47-48 (2013).

Proneth A., Schnitzbauer A.A., Zeman F., Foerster J.R., Holub I., Arbogast H., Bechstein W.O., Becker T., Dietz C., Guba M., Heise M., Jonas S., Kersting S., Klempnauer J., Manekeller S., Müller V., Nadalin S., Nashan B., Pascher A., Rauchfuss F., Ströhle

Extended pancreas donor program - the EXPAND study rationale and study protocol.

Transplantation Research 2 (1), 12 (2013).

Rueb J., Kühn P., Viebahn R., Wunsch A.

Predicting quality of deceased donor kidneys: the harvesting surgeon as a prognostic factor?

Transplantation Proceedings 45 (4), 1360-1362 (2013).

Schenker P., Viebahn R.

Perspektiven der kombinierten Pankreas-Nieren-Transplantation.

Deutsche Medizinische Wochenschrift 138, 958-963 (2013).

Schenker P., Walter M., Jazra M., Kuehn P., Kykalos S., Wunsch A., Viebahn R.

125 cases of duodenoduodenostomy in pancreas transplantation: a single-center experience of an alternative enteric drainage.

Transplant International 26 (S1), 14 (2013).

Teodoridis A., Schenker P., Wunsch A., Viebahn R.

Metabolic follow-up four years after simultaneous pancreas-kidney transplantation with portal venous versus systemic venous drainage.

Transplant International 26 (S1), 48 (2013).

Viebahn R., Greif-Higer G.

Neuer Transplantationskodex: Verantwortung gegenüber Spendern und Empfängern.

Deutsches Ärzteblatt 110 (51-52), A-2465 (2013).

Viebahn R.

The german transplant scandal: reflections of an insider.

Transplant International 26 (S1), 10 (2013).

Viebahn R., Wunsch A., Michalski S., Kühn P., Porwol D., Goetting S., Schenker P.
OLD-TO OLD – Allocation in pancreas transplantation –impact of different cutoff ages.
Transplant International 26 (S1), 5 (2013).

Walter M., Klein T., Jazra M., Kykalos S., Kühn P., Wunsch A., Viebahn R., Schenker P.

125 Cases of Duodenoduodenostomy in Pancreas Transplantation: A Single-Center Experience of an Alternative Enteric Drainage.

American Journal of Transplantation 13 (5), 442 (2013).

Quang M. N., Krüger B., Wenning M., Krüger C. D., Tokmak F., Kisters K., Wunsch A., Schenker P., Viebahn R., Krämer B.K.

Autotransplantation for the treatment of severe renal artery stenosis in a solitary kidney after repeated percutaneous transluminal angioplasty: a case report.

Clinical nephrology 78 (5), 418-422 (2012).

Roedel C., Liersch T., Becker H. et al., German Rectal Cancer Study Group (Viebahn R., Member).

Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.

Lancet Oncology 13 (7), 679-687 (2012).

Rueb J., Kühn P., Viebahn R., Wunsch A.

Predicting Quality of Deceased Donor Kidneys: The Explant Surgeon as a Prognostic Factor?

Transplantation 94 (10S), 923 (2012).

Schenker P., Ziarna S., Jazra M., Grzella S., Hempel C., Teodoridis A., Viebahn R.

Thymoglobulin Induction and Calcineurin Inhibitor Delay in the Eurotransplant Senior Kidney Program - A 10-Year Single Center Experience.

Transplantation 94 (10S), 976-977 (2012).

Wunsch A., Kühn P., Schenker P., Viebahn R.

Massive Bleeding as a Late Complication of Combined Pancreas-Kidney Transplantation.

Transplantation 94 (10S), 698 (2012).